compositions and methods comprising a psilocybin derivative

专利摘要:
this disclosure refers to new compositions and methods that include a psilocybin derivative. in one embodiment, as compositions disclosed herein, they are used for a neurotransmitter receptor regulation module, for example, a serotonin receptor. in one embodiment, the compositions disclosed herein comprise purified, for example, a purified psilocybin derivative, a purified cannabinoid or purified terpene.
公开号:BR112019016489A2
申请号:R112019016489
申请日:2018-02-09
公开日:2020-04-07
发明作者:R Chedeayne Andrew
申请人:Caamtech Llc；
IPC主号:

专利说明:

“COMPOSITIONS AND METHODS UNDERSTANDING A PSILOCIBINE DERIVATIVE”
FIELD OF THE INVENTION [001] This disclosure relates to the psilocybin technology which, at the time of this description, is mainly related to mycology, mushroom cultivation, natural mushroom preparations and (in some cases) the psilocybin of the isolated compound.
FUNDAMENTALS [002] Many people suffer from psychological or mood disorders, such as depression, anxiety, compulsion and post-traumatic stress disorders, around the world. Many of these conditions are believed to involve an individual's serotonin system - including interactions between (A) the neurotransmitter serotonin (often abbreviated as 5-HT) and (B) several different subtypes of neurotransmitter serotonin receptors found in the human body.
[003] A variety of compositions are known to modulate activity at serotonin receptors. Various pharmaceutical products (antidepressants, serotonin reuptake inhibitors, selective serotonin reuptake inhibitors, etc.) are available. In 2014, the BetterCommunication Company projected that the global market for drugs for mental disorders would be about $ 77.1 billion by 2018 and recorded a compounded annual five-year growth rate of 2.3% from 2013 to 2018 Almost all of these pharmaceutical products target neurotransmitters, for example, serotonergic receptors, adrenergic receptors, dopaminergic receptors, etc., and in different ways. All ten leading pharmaceuticals in the treatment of mood disorders (such as depression, obsessive-compulsive disorder and / or anxiety disorders) target the serotonin pathways.
[004] However, despite their unquestionable popularity and commercial success, users of these pharmaceutical products are dissatisfied with their
Petition 870190082150, of 22/08/2019, p. 3/121
2/99 long onset times, severe side effects and low effectiveness. In many cases, these drugs are harmful to the user. For example, many people who take controlled serotonin drugs report feeling suicidal thoughts, sexual dysfunction, fatigue, high blood pressure, blurred vision, abnormal heart rate, nausea and weight gain.
[005] The so-called "magic or psychedelic or hallucinogenic mushrooms" are taken recreational by thousands of people in the United States. Psilocybin (also known as 4-phosphoryloxy-N, N-dimethyltryptamine or [3- (2trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate) is considered the most abundant psychoactive compound within a "magic mushroom" . Psilocin (4-hydroxyΝ, Ν-dimethyltryptamine) is considered the second most abundant compound. Many within the scientific community consider psilocin to be the only active ingredient in "magic mushrooms", arguing that psilocybin serves only as a prodrug and has no activity in itself. No conclusive studies have been carried out to substantiate or exclude this theory.
[006] When formulated and administered correctly, psilocin and psilocybin provide rapid and lasting changes in a person's mood. These effects can be achieved with only minor side effects, low potential for addiction, low potential for abuse and low risk of toxicity.
[007] Currently, the state of the art for psilocybin technology is not advanced. Although a group of studies uses purified psilocybin as a single active pharmaceutical ingredient, virtually no work has been done on formulating psilocybin in pharmaceuticals for the treatment of mental disorders. In addition to some studies on purified psilocybin, no effort has been made to modulate its properties with formulation agents or other ingredients. No efforts were made to formulate specific combinations or doses of psilocybin derivatives or combinations with other active molecules. Were not
Petition 870190082150, of 22/08/2019, p. 4/121
3/99 efforts were made to formulate psilocybin in compositions capable of modifying activity in one or more neurotransmitter receptors.
[008] Psilocybin techniques focus mainly on the cultivation and consumption of mushrooms. Unfortunately, collecting and eating mushrooms can be dangerous because of the difficulties in distinguishing the desired mushroom species from similar species. For example, mushrooms of the genus Psilocybe are easily confused with toxic ones. Misidentification of Psilocybe mushrooms results in severe illness and death each year.
[009] Even when magic mushrooms are properly identified, these mushrooms vary widely in terms of the concentration of psilocybin, psilocin and other active ingredients (often overlooked). Therefore, the administration of a specific compound or a particular dose using mushrooms is not possible due to the variability of their chemical composition.
[0010] Furthermore, even when magic mushrooms are properly identified, they are prone to contamination. Contamination can result in problems, such as unwanted side effects, for example, a wood lover paralysis.
[0011] Very few studies on the pharmacology of psilocybin have been carried out due to the general understanding of the state of the art in not looking for psilocybin formulations. On the contrary, the current state of the art focuses on "magic mushrooms" almost exclusively. The highest authorities on the subject in the United States still maintain that psilocybin has "no beneficial purpose" and carries a "high potential for abuse".
[0012] Until recently, few studies on the development of therapeutic methods including psilocybin have been done. Recent efforts have shown that taking pure isolated psilocybin is promising for the treatment of various psychological conditions, such as post-traumatic stress, anxiety, addiction, depression and
Petition 870190082150, of 22/08/2019, p. 5/121
4/99 compulsion. On November 6, 2017, Newsweek magazine explained the state of the art as follows: “Magic mushrooms (active psilocybin) were used as experimental medical treatment in the 1960s, and some researchers are again turning to them for healing. For example, in a pilot study in 2011, mushrooms appeared to have a positive effect on cancer patients with anxiety. In 2016, a study demonstrated its use in the treatment of depression ”.
[0013] Bearing in mind that research on psilocybin is a relatively small area, virtually no work on the formulation of psilocybin or the pharmacological study of psilocybin, its derivatives and new formulations comprising them has been carried out. The study, formulation and adequate dosage of psilocybin and its derivatives would provide significant benefits in the treatment of mood and neurological disorders, such as depression, attention deficit hyperactivity disorder, compulsive disorder and / or anxiety disorder.
[0014] There is a need for new compositions and methods comprising one or more of 3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2 -trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N, N-trimethyltryptamine, [3- (2-methylaminoethyl) -1 H-indol4-yl] dihydrogen phosphate, 4 -hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and / or 4-hydroxytryptamine in a precise dosage formulation.
[0015] There is still a need for formulations that combine these formulations with other molecules that affect the activity of neurotransmitters.
[0016] There is a need for better methods and compositions for targeting and / or modulating activity in one or more neurotransmitter receptors. Recently, “magic mushrooms” and a molecule contained in them have shown potential application in this area. However, before these
Petition 870190082150, of 22/08/2019, p. 6/121
5/99 molecules can be transformed into effective treatments, they need to be properly studied and formulated in compositions that provide consistent and specific effects, for example, a specific activity in a neurotransmitter receptor.
[0017] Therefore, the state of the art for psilocybin has an unmet need for formulated psilocybin compositions. This need can be met by isolating and identifying molecules in magic mushrooms and studying their activity using cellular pharmacology.
DETAILED DESCRIPTION [0018] New methods and compositions comprising a psilocybin derivative are described in this document. In one embodiment, the compositions described in this document comprise one or more psilocybin derivatives chosen from the following: [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy -N, N-dimethyltryptamine, [3- (2methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3 (aminoethyl) -l H-indol-4-yl] dihydrogen phosphate, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, N-trimethyltryptamine.
[0019] In one embodiment, the compositions described in this document comprise one or more purified psilocybin derivatives chosen from: [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-methylaminoethyl) -1 H-indol-4-iI] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indole- 4-yl] dihydrogen phosphate, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, Ntrimethyltryptamine.
[0020] In one embodiment, the methods and compositions described in this document comprise the regulation of the activity of a neurotransmitter receptor with a first dosage form comprising a
Petition 870190082150, of 22/08/2019, p. 7/121
6/99 first purified psilocybin derivative. In one embodiment, the methods and compositions described in this document comprise administering a first dosage formulation comprising a second purified psilocybin derivative. In one embodiment, the methods described in this document comprise administering a first dosage form comprising a first purified cannabinoid. In one embodiment, the methods described in this document comprise administering a first dosage formulation comprising a purified first terpene. In one embodiment, the methods described in this document comprise administering a first dosage formulation comprising a modulator of neurotransmitter activity. In one embodiment, the methods described in this document comprise administering a first dosage formulation comprising a first purified psilocybin derivative, a first purified cannabinoid, a first purified terpene and / or a neurotransmitter activity modulator.
[0021] In one embodiment, the methods described in this document comprise administering the compositions described in this document. In one embodiment, the methods described in this document comprise treating a psychological disorder, for example, an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions described in this document, for example, a composition with a or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes and / or a combination thereof. In one embodiment, the methods described in this document comprise treating a psychological disorder, for example, an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions described in this document and a neurotransmitter activity modulator, for example. example, a serotonergic drug, a drug
Petition 870190082150, of 22/08/2019, p. 8/121
7/99 dopaminergic, etc.
[0022] New compositions comprising a first purified psilocybin derivative and a serotonergic drug are described in this document. In one embodiment, the compositions described in this document comprise a first purified psilocybin derivative and a serotonergic drug present in intentionally developed and unnatural molar ratios.
[0023] New compositions comprising a first purified psilocybin derivative and a first purified cannabinoid are described in this document. In one embodiment, the compositions described in this document comprise a first purified psilocybin derivative and a first purified cannabinoid present in intentionally developed and unnatural molar ratios.
[0024] New compositions comprising a first purified psilocybin derivative and a first purified terpene are described in this document. In one embodiment, the compositions described in this document comprise a first purified psilocybin derivative and a first purified terpene present in intentionally developed and unnatural molar ratios.
[0025] New compositions comprising a first purified psilocybin derivative, a first purified cannabinoid, and a first purified terpene are described in this document. In one embodiment, the compositions described in this document comprise a first purified psilocybin derivative, a first purified cannabinoid and a first purified terpene present in intentionally developed and unnatural molar ratios.
[0026] New compositions comprising a first derivative of
Petition 870190082150, of 22/08/2019, p. 9/121
8/99 purified psilocybin, a first purified cannabinoid and a second purified cannabinoid are described in this document. In one embodiment, the compositions described in this document comprise a first purified psilocybin derivative, a first purified cannabinoid and a second purified cannabinoid present in intentionally developed and unnatural molar ratios.
[0027] As used here, the term "chitin" refers to a polymer found mainly in the cell walls of fungi. In one embodiment, the chitin is translucent. In one embodiment, chitin is malleable. In one embodiment, chitin is resilient. In one embodiment, chitin is durable. In one embodiment, chitin contains nitrogen. In one embodiment, the compositions described in this document comprise between 0-10% by weight of chitin, as determined by the dry weight. In one embodiment, the compositions described in this document comprise between 0-5% by weight of chitin, as determined by dry weight. In one embodiment, the compositions described in this document comprise less than 1% by weight of chitin, as determined by dry weight.
[0028] In one embodiment, the compositions described in this document comprise between 0-15% by weight of water, as determined by the dry weight. In one embodiment, the compositions described in this document comprise between 0-10% by weight of water, as determined by the dry weight. In one embodiment, the compositions described in this document comprise between 0-5% by weight of water, as determined by the dry weight. In one embodiment, the compositions described in this document comprise between 0-1% by weight of water, as determined by the dry weight.
[0029] As used here, the term "protein" refers to a large molecule that comprises one or more chains of amino acids (polypeptides). In
Petition 870190082150, of 22/08/2019, p. 12/101
9/99 an embodiment, a protein performs a function within an organism, for example, it catalyzes metabolic reactions, facilitates DNA replication, responds to stimuli, transports molecules, etc. In one embodiment, a protein serves as a structural component in an organism.
[0030] In one embodiment, the compositions described in this document comprise between 0-15% by weight of protein, as determined by dry weight. In one embodiment, the compositions described in this document comprise between 0-10% by weight of protein, depending on the dry weight. In one embodiment, the compositions described in this document comprise between 0-5% by weight of protein, as determined by the dry weight. In one embodiment, the compositions described in this document comprise between 0-1% by weight of protein, as determined by the dry weight. In one embodiment, the compositions described in this document comprise less than 5% by weight of protein, as determined by the dry weight.
[0031] As used here, the term dry weight refers to a measurement of the mass of a sample after removing all or substantially all of the liquid from the sample. In one embodiment, removing liquid comprises dehydrating, heating, stirring, filtering and / or any other method suitable for liquid water. In one embodiment, the dry weight is measured in pounds. In one embodiment, the dry weight is measured in ounces. In one embodiment, dry weight is measured in grams, for example, milligrams, kilograms, etc.
[0032] In one embodiment, the compositions described in this document are in the form of a dry powder.
[0033] As used here, the term "dry powder" refers to a substance composed of fine particles and which contains little or no liquid material. In
Petition 870190082150, of 22/08/2019, p. 12/111
In one embodiment, a dry powder is derived by evaporating the alcohol from a solution leaving the particles dry. In one embodiment, a dry powder is a precipitate from a solution. In one embodiment, a dry powder is a solid collected from a plant (for example, mushrooms) and sprayed into a powder, for example, using a mortar and pestle.
[0034] In one embodiment, a dry powder is composed of particles with a crystalline structure.
[0035] In one embodiment, a dry powder is composed of pure crystals.
[0036] In one embodiment, a dry powder is composed of a mixture of crystals.
[0037] In the context of this description, any method for removing liquid is suitable for making a dry powder, for example, heating, mixing, filtering, evaporation, etc.
[0038] In one embodiment, the compounds described in this document are in the form of dry powder, for example, a psilocybin derivative, a cannabinoid, a terpene, etc.
[0039] In one embodiment, a dry powder comprises an anti-aggregating agent, for example, a desiccant.
[0040] In the context of this description, it is understood that a sample may comprise small amounts of liquid that are insignificant in the final measurement of a sample. In one example, it is acceptable for a composition of this description to comprise up to 1% water, measured by percentage by mass.
[0041] As used here, the term "percentage by mass", or "percent by mass", "% by mass", etc., refers to the amount of a compound in relation to the entire mass of a sample, such as a fraction of 100. In one embodiment, the mass percentage is calculated with the following formula for a
Petition 870190082150, of 22/08/2019, p. 12/121
11/99 compound of interest:
(Mass of the compound of interest in grams) / (total mass of the composition in grams) x 100% [0042] In one example, a composition weighs 100 g and comprises 0.5 g of a first purified psilocybin derivative, 8 g of a first purified cannabinoid, and 2.5 g of a first purified terpene. The mass percentage of the first purified psilocybin derivative, the first purified cannabinoid and the first purified terpene are 0.5%, 8% and 2.5%, respectively.
[0043] In one example, for a 25 g composition comprising 2 g of a psilocybin derivative, the amount of a psilocybin derivative within a composition is determined by the following:
2.0 g of psilocybin derivative + 25.0 g of composition x 100% = 8.0% [0044] In the context of this description, the term “purified” means separated from other materials, such as plant or fungal material, by example, protein, chitin, cellulose or water. In one embodiment, the term "purified" refers to a compound substantially free of other materials. In one embodiment, the term "purified" refers to the compound that is substantially free of a second tryptamine compound. In one embodiment, the term "purified" refers to a compound substantially free of histidine. In one embodiment, the term "purified" refers to a compound substantially free of biological material, such as mold, fungus, plant or bacteria. In one embodiment, the term "purified" refers to a compound substantially free of a paralytic (paralytic).
[0045] In one embodiment, the term purified refers to a compound or composition that has been crystallized.
[0046] In one embodiment, the term "purified" refers to a compound or composition that has been subjected to chromatography, for example,
Petition 870190082150, of 22/08/2019, p. 12/13
12/99 by gas chromatography, liquid chromatography (eg LC, HPLC, etc.), etc.
[0047] In one embodiment, the term purified refers to a compound or composition that has been distilled.
[0048] In one embodiment, the term "purified" refers to a compound or composition that has been sublimated.
[0049] In one embodiment, the term "purified" refers to a compound or composition that has undergone two or more stages selected from: crystallization, chromatography, distillation or sublimation.
[0050] In one embodiment, the term "purified" refers to a compound that is 80-100% pure, which means that the compound constitutes 80-100% of the total mass of the composition.
[0051] In one embodiment, the term "purified" refers to a compound that is 90-100% pure, which means that the compound constitutes 90-100% of the total mass of the composition.
[0052] In one embodiment, the term purified refers to a compound that is 95-100% pure, which means that the compound constitutes 95-100% of the total mass of the composition.
[0053] In one embodiment, the term purified refers to a compound that is 99-100% pure, which means that the compound constitutes 99-100% of the total mass of the composition.
[0054] In one embodiment, the term purified refers to a compound that is 99.9-100% pure, which means that the compound constitutes 99.9-100% of the total mass of the composition.
[0055] In addition, the compounds described in this document are often found in forms called "conjugate" or "derivatives" during chemical analysis. In one example, a psilocybin derivative is in the form of a glucuronide derivative in human serum assays. Enzymatic hydrolysis converts the
Petition 870190082150, of 22/08/2019, p. 12/14
13/99 glucuronide derivative in a non-glucuronide form. Before extraction, hydrolysis of the glucuronide derivative may be useful.
[0056] For example, one can deduce the concentration of psilocin by GC / MS, using beta-glucuronidase to release psilocin from its conjugate (also known as the glucuronide derivative form) in the urine and then use MSTFA (N-methyl-N-trimethylsilyltrifluoroacetamide) for derivation of psilocin in its trimethylsilyl derivative.
[0057] GC / MS can be used for the identification and quantification of psilocin in biological specimens.
[0058] Psilocin and psilocybin can also be identified using liquid chromatography with or without mass mass spectrometry (LC / MS / MS). When using LC / MS, derivation of the method before analysis is generally not necessary. Liquid chromatography combined with serial mass spectrometry for analysis of psilocin and psilocybin in psychoactive mushrooms can provide useful samples as well. All data indicate that the presence and amount of psychoactive compounds within the naturally occurring samples are considered to be highly variable.
[0059] New compositions are described in this document comprising specific ratios of [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4hydroxy-N, N-dimethyltryptamine, [3- (2-trimethylaminoethyl ) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N, N-trimethyltryptamine, [3- (2-methylaminoethyl) -1 H-indol-4yl] dihydrogen phosphate, 4-hydroxy-N -methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and / or 4-hydroxytryptamine; and its salts and derivatives.
[0060] As used here, the term "specific ratio" refers to the amount of a compound in relation to the amount of another compound or compounds. In one embodiment, there is a ratio of about 1: 1 between [3 (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, NPetition 870190082150, from 22/08 / 2019, p. 12/151
14/99 dimethyltryptamine. In one embodiment, a specific ratio of the compounds is measured by the same unit, for example, grams, kilograms, pounds, ounces, etc. In one embodiment, a specific ratio of the compounds is measured in moles, i.e., molar ratios or molar ratios.
[0061] In one example, there is a specific ratio of 1 kg to 2 grams between [3 (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, Ndimethyltryptamine.
[0062] New compositions comprising specific amounts of [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2 -trimethylaminoethi I) -1 H-indole-4-i] dihydrogen phosphate, 4-hydroxy-N, N, N-trimethyltryptamine, [3- (2-methylaminoethyl) -1 H-indol-4yl] dihydrogen phosphate, 4 -hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and / or 4-hydroxytryptamine; and its salts and derivatives.
[0063] As used here, the term specific quantity refers to the quantity of a compound or compounds. In one embodiment, a specific amount is the combined amount of two compounds within a sample. In one embodiment, a specific amount is measured by dry weight. In one embodiment, the specific quantity has 1,2, 3 or 4 significant values.
[0064] New compositions are described in this document comprising little or no deviation (between samples of said compositions) of one or more of the following molecules: [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N, N-trimethyltryptamine, [3- (2- methylaminoethyl) -1 H-indol4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and / or 4-hydroxytryptamine; and its salts and derivatives.
[0065] This document describes a new composition,
Petition 870190082150, of 22/08/2019, p. 12/161
15/99 comprising:
a first purified psilocybin derivative; wherein the first purified psilocybin derivative is chosen from [[3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3- (2- trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, N-trimethyltryptamine; and a second purified psilocybin derivative; wherein the second purified psilocybin derivative is chosen from [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-methylaminoethyl) - 1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3- (2-trimethylaminoethyl )] - 1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, N-trimethyltryptamine.
[0066] In one embodiment, the compositions described in this document comprise a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[0067] In one embodiment, the compositions described in this document comprise a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[0068] In one embodiment, the compositions described in this document comprise a molar ratio of about 1,000: 1 to about 1: 1000 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[0069] In one embodiment, the compositions described in this document comprise a molar ratio of about 10,000: 1 to about 1: 10,000
Petition 870190082150, of 22/08/2019, p. 12/17
16/99 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[0070] In one embodiment, the first purified psilocybin derivative is [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0071] In one embodiment, the first purified psilocybin derivative is 4-hydroxy-N, N-dimethyltryptamine.
[0072] In one embodiment, the first purified psilocybin derivative is [3- (2-methylaminoethyl) -1 H-indol-4-i] dihydrogen phosphate.
[0073] In one embodiment, the first purified psilocybin derivative is 4-hydroxy-N-methyltryptamine.
[0074] In one embodiment, the first purified psilocybin derivative is [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0075] In one embodiment, the first purified psilocybin derivative is 4-hydroxytryptamine.
[0076] In one embodiment, the first purified psilocybin derivative is [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0077] In one embodiment, the first purified psilocybin derivative is 4-hydroxy-N, N, N-trimethyltryptamine.
[0078] As used herein, the term "psilocybin derivative" refers to a compound having a nuclear structure similar to the more well-known [3- (2 dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate compound like “psilocybin”. In one embodiment, a psilocybin derivative is dephosphorylated, such as a phenol or a derivative thereof. In one embodiment, a psilocybin derivative comprises zero, one, two or three alkyl groups covalently attached to the nitrogen atom in the aminoethyl group. In one embodiment, a psilocybin derivative comprises an amine group (-NH2). In one embodiment, a psilocybin derivative comprises a group
Petition 870190082150, of 22/08/2019, p. 12/181
17/99 hydroxyl (-OH). In one embodiment, a psilocybin derivative comprises a carbonyl group. In one embodiment, a psilocybin derivative comprises an ester group. In one embodiment, a psilocybin derivative comprises a carboxyl group. In one embodiment, a psilocybin derivative comprises an amide group.
[0079] In one embodiment, a psilocybin derivative within the compositions described in this document is a compound defined by the following structural formula A:
Hi: ¾
Γ (where each Ri, R2, R ₃ , R4, Rs, Re, R7, Rs, R9 and R10 is chosen from an electron pair, a hydrogen atom, an alkyl, an alkenyl, an alkynyl, a phenyl, a halide, a hydroxyl, a carbonyl, an aldehyde, a haloformyl, a carbonate ester, a carboxylate, a carboxyl, an ester, a hydroperoxy, a peroxy, an ether, a hemiacetal, a hemicetal, an acetal, a ketal , an orthoester, a methylenedioxy, an orthocarbonate ester, carboxamide, an amine, an imine, an amide, an azide, an azo, a cyanate, a nitrate, a nitrile, an isonitrile, a nitrous-oxy, a nitro, a pyridyl , a thiol, a sulfide, a sulfinyl, a sulfonyl, a thiocyanate, a carbonothioyl or a phosphate.
[0080] In one embodiment, a psilocybin derivative is a compound defined by structural formula A, in which each R1, R2, and R3 is independently chosen from an electron pair, a hydrogen, or an alkyl group; where R4 is hydrogen; wherein Rs is selected from a hydroxyl group, an ether, or a phosphate; and where each Rs, R7, Rs, R9 and R10 is hydrogen.
[0081] In one embodiment, a psilocybin derivative is a
Petition 870190082150, of 22/08/2019, p. 12/191
18/99 compound defined by structural formula A, in which each Ri, R2, and R3 is independently chosen from an electron pair, a hydrogen, or an alkyl group; where each R4 and Rs is hydrogen; where Re is selected from a hydroxyl group, an ether, or a phosphate; and where each Rz, R3, R9 and R10 is hydrogen.
[0082] In one embodiment, a first psilocybin derivative is [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0083] As used herein, the term "[3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate" refers to a compound, and / or its salts, with the following formula structural:
[0084] [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate is often described by the name "psilocybin". Psilocybin is a psychoactive prodrug often found in mushrooms of the genus Psilocybe. See American Chemical Society, Molecule of the Week (October 2, 2017). When ingested, psilocybin is converted to psilocin through chemical and / or biological processes in the human body. Id. In the context of this description, unless otherwise stated, 0 [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate may be present in its protonated or deprotonated form (salt or free base) or their mixtures depending on the environment, for example, the pH of the solution or composition.
[0085] In one embodiment, a first psilocybin derivative is 4-hydroxy-N, N-dimethyltryptamine.
[0086] As used herein, the term 4-hydroxy-N, N-dimethyltryptamine refers to a compound, and / or salts thereof, with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 12/20
19/99
J
OH • i

H [0087] 4-hydroxy-N, N-dimethyltryptamine is also known by the name psilocin. In the context of this description, unless otherwise indicated, 4-hydroxyΝ, Ν-dimethyltryptamine can be present in its protonated or deprotonated form (salt or free base) or mixtures depending on the environment, for example, the pH of the solution or composition.
[0088] In one embodiment, a first psilocybin derivative is [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0089] As used herein, the term "[3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate" refers to a compound, and / or its salts, with the following formula structural:
[0090] In the context of this description, unless otherwise indicated, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate may be present in its protonated or deprotonated form (salt or free base) or its mixtures depending on the environment, for example, the pH of the solution or composition.
[0091] In one embodiment, a first psilocybin derivative is 4-hydroxy-N, N, N-trimethyltryptamine.
[0092] As used herein, the term 4-hydroxy-N, N, N-trimethyltryptamine
Petition 870190082150, of 22/08/2019, p. 12/21
20/99 refers to a compound, and / or salts thereof, with the following structural formula:
pH

H [0093] In the context of this description, unless otherwise indicated, a4-hydroxyΝ, Ν, Ν-trimethyltryptamine may be present in its protonated or deprotonated forms (salt or free base) or mixtures depending on the environment, for example, pH of the solution or composition.
[0094] In one embodiment, a first psilocybin derivative is [3- (2-methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[0095] As used herein, the term “[3- (2-methylaminoethyl) -1 H-indol-4-iI] dihydrogen phosphate” refers to a compound, and / or the salts thereof, with the following structural formula :
H x

H [0096] In the context of this description, unless otherwise indicated, [3- (2methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate may be present in its protonated or deprotonated form (salt or free base) or their mixtures depending on the environment, for example, the pH of the solution or composition.
[0097] In one embodiment, a first psilocybin derivative is 4-hydroxy-N-methyltryptamine.
[0098] As used herein, the term 4-hydroxy-N-methyltryptamine refers to
Petition 870190082150, of 22/08/2019, p. 12/22
21/99 to a compound, and / or salts thereof, with the following structural formula:
[0099] In the context of this description, unless otherwise indicated, a4-hydroxyN-methyltryptamine may be present in its protonated or deprotonated forms (salt or free base) or mixtures depending on the environment, for example, the pH of the solution or composition.
[00100] In one embodiment, a first psilocybin derivative is [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate.
[00101] As used herein, the term "[3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate" refers to a compound, and / or its salts, with the following structural formula:
[00102] In the context of this description, unless otherwise specified, [3 (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate may be present in its protonated or deprotonated form (salt or free base) or mixtures thereof depending on the environment, for example, the pH of the solution or composition.
[00103] In one embodiment, a first psilocybin derivative is 4-hydroxytryptamine.
[00104] As used herein, the term 4-hydroxytryptamine refers to a
Petition 870190082150, of 22/08/2019, p. 12/23
22/99 compound, and / or salts thereof, with the following structural formula: H z «
M '>
[00105] In the context of this description, unless otherwise indicated, 4-hydroxytryptamine may be present in its protonated or deprotonated form (salt or free base) or mixtures depending on the environment, for example, the pH of the solution or composition.
[00106] As used here, the term salt refers to a neutralized ionic compound. In one embodiment, a salt is formed from the neutralization of acids and bases. In one embodiment, a salt is electrically neutral.
[00107] In one embodiment, the compositions and methods described in this document comprise administering a first cannabinoid. In one embodiment, a first cannabinoid is a first purified cannabinoid.
[00108] As used here, the term cannabinoid refers to a compound of a class of molecules commonly found in plants of the genus Cannabis and its derivatives. In one embodiment, the cannabinoid is endogenous to an animal, that is, an endocannabinoid. In one embodiment, the cannabinoid is derived from a plant, for example, a plant of the genus Cannabis, that is, a phytocannabinoid. In one embodiment, the cannabinoid is artificially produced in a laboratory, that is, a synthetic cannabinoid. Many cannabinoids can be identified by the term cannabi in their chemical name. There are at least 113 different cannabinoids isolated from Cannabis, with varied effects (similar and different).
[00109] Examples of cannabinoids in the context of this invention include
Petition 870190082150, of 22/08/2019, p. 12/24
23/99 the following molecules: cannabichromene (CBC), cannabichromenic acid (CBCA), cannabicromevarin (CBCV), cannabicromevarinic acid (CBCVA), cannabicyclol (CBL), cannabicyclic acid (CBLA), cannabicyclovarin (CBLV), cannabidiol (CBD), cannabidiol monomethyl ether (CBDM), cannabidiolic acid (CBDA), cannabidiorcol (CDB-C1), cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabielsoic acid (CBEA) -A), cannabigerol (CBG), cannabigerol monomethyl ether (CBGM), cannabigerolic acid (CBGA), cannabigerolic acid monomethyl ether (CBGAM), cannabigerovarin (CBGV), cannabigerovarinic acid (CBGVA), cannabinodiol (CBND), cannabinodivarin (CBND), cannabinodivarin (CBND) ), cannabinol (CBN), cannabinol methyl ether (CBNM), cannabinol-C2 (CBN-C2), cannabinol-C4 (CBN-C4), cannabinolic acid (CBNA), cannabiorcol (CBN-C1), cannabivarin (CBV), cannabitriol (CBT), cannabitriolvarin (CBTV), 10-ethoxy-9-hydroxy-delta-6atetrahydrocannabinol, canbicitran (CBT), cannabiripsol (CBR), 8,9-di -hydroxy-delta-6atetrahydrocannabinol, delta-8-tetrahydrocannabinol (A8-THC), delta-8tetrahydrocannabinolic acid (A8-THCA), delta-9-tetrahydrocannabinol (THC), delta-9tetrahydrocannabinol-C4-acid (C4) -9-tetrahydrocannabinolic A (THCA-A), delta-9-tetrahydrocannabinolic acid B (THCA-B), delta-9tetrahydrocannabinolic acid-C4 (THCA-C4), delta-9-tetrahydrocannabiorcol (THC-C1), delta-acid 9-tetrahydrocannabiorcolic (THCA-C1), delta-9-tetrahydrocannabivarin (THCV), delta-9-tetrahydrocannabivarinic acid (THCVA), 10-oxo-delta-6a-tetrahydrocannabinol (OTHC), cannabican (CB) , cannabiglendol, delta-9-cystetrahydrocannabinol (cis-THC), trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC), dehydrocannabifuran (DCBF) and 3,4,5,6-tetrahydro-7-hydroxy-alpha- alpha-2-trimethyl-9-npropyl-2,6-methane-2H-1-benzoxocin-5-methanol.
[00110] In one embodiment, the term cannabinoid refers to a compound chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV or CBGVA.
Petition 870190082150, of 22/08/2019, p. 12/25
24/99 [00111] As used here, the term THC, or tetrahydrocannabinol, refers to a compound with the following structural formula:
í
[00112] In the context of this description, the term THC includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a THC formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THC and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering THC and a purified psilocybin first derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THC and a first purified psilocybin derivative.
[00113] As used here, the term THCA refers to a compound with the following structural formula:
[00114] In the context of this description, the term “THCA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a THCA formulation and a
Petition 870190082150, of 22/08/2019, p. 12/26
25/99 first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering THCA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCA and a first purified psilocybin derivative.
[00115] As used here, the term THCV refers to a compound with the following structural formula:
[00116] In the context of this description, the term THCV includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a THCV formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCV and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering THCV and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCV and a first purified psilocybin derivative.
[00117] As used here, the term THCVA refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 12/27
26/99
[00118] In the context of this description, the term THCVA includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a THCVA formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCVA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering THCVA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified THCVA and a first purified psilocybin derivative.
[00119] As used here, the term CBC refers to a compound with the following structural formula:
[00120] In the context of this description, the term CBC includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBC formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBC and a first psilocybin derivative. In one embodiment, the compositions and
Petition 870190082150, of 22/08/2019, p. 12/28
27/99 methods described in this document comprise administering CBC and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBC and a first purified psilocybin derivative.
[00121] As used here, the term CBCA refers to a compound with the following structural formula:
[00122] In the context of this description, the term “CBCA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBCA formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBCA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCA and a purified psilocybin first derivative.
[00123] As used here, the term CBCV refers to a compound with the following structural formula:

Petition 870190082150, of 22/08/2019, p. 12/29
28/99 [00124] In the context of this description, the term CBCV includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBCV formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCV and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBCV and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCV and a first purified psilocybin derivative.
[00125] As used here, the term CBCVA refers to a compound with the following structural formula:
[00126] In the context of this description, the term CBCVA includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBCVA formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCVA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBCVA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBCVA and a purified psilocybin first derivative.
[00127] As used here, the term CBD refers to a compound with
Petition 870190082150, of 22/08/2019, p. 12/30
29/99 the following structural formula:
[00128] In the context of this description, the term “CBD” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBD formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBD and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBD and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBD and a purified psilocybin first derivative.
[00129] As used here, the term CBDA refers to a compound with the following structural formula:
[j OH O
JL [00130] In the context of this description, the term “CBDA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of CBDA and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering purified CBDA and a
Petition 870190082150, of 22/08/2019, p. 12/31
30/99 first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBDA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBDA and a purified psilocybin first derivative.
[00131] As used here, the term CBDV refers to a compound with the following structural formula:
HO [00132] In the context of this description, the term “CBDV” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of CBDV and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBDV and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBDV and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBDV and a purified psilocybin first derivative.
[00133] As used here, the term CBDVA refers to a compound with the following structural formula:
OH O
H
OH
HO '
Petition 870190082150, of 22/08/2019, p. 12/31
31/99 [00134] In the context of this description, the term “CBDVA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of CBDVA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBDVA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBDVA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBDVA and a purified psilocybin first derivative.
[00135] As used here, the term CBG refers to a compound with the following structural formula:
[00136] In the context of this description, the term “CBG” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBG formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBG and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBG and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBG and a purified psilocybin first derivative.
[00137] As used here, the term CBGA refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 12/31
32/99
[00138] In the context of this description, the term “CBGA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of CBGA and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering purified CBGA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBGA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBGA and a purified psilocybin first derivative.
[00139] As used here, the term CBGV refers to a compound with the following structural formula:
[00140] In the context of this description, the term “CBGV” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a CBGV formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBGV and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBGV and a first purified psilocybin derivative. In one embodiment, the compositions and
Petition 870190082150, of 22/08/2019, p. 12/31
The methods described in this document comprise administering purified CBGV and a first purified psilocybin derivative.
[00141] As used here, the term CBGVA refers to a compound with the following structural formula:
[00142] In the context of this description, the term “CBGVA” includes any derivative and / or salt thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of CBGVA and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering purified CBGVA and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering CBGVA and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering purified CBGVA and a first purified psilocybin derivative.
[00143] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified cannabinoid .
[00144] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified cannabinoid .
[00145] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of
Petition 870190082150, of 22/08/2019, p. 12/35
34/99 about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified cannabinoid.
[00146] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified cannabinoid .
[00147] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified cannabinoid .
[00148] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified cannabinoid .
[00149] In one embodiment, the compositions and methods described in this document comprise a first purified psilocybin derivative, a first purified cannabinoid, and a second purified cannabinoid.
[00150] In one embodiment, the second purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV or CBGVA.
[00151] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[00152] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the
Petition 870190082150, of 22/08/2019, p. 12/36
35/99 sum of the first purified cannabinoid and the second purified cannabinoid.
[00153] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[00154] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[00155] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[00156] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[00157] In one embodiment, the compositions and methods described in this document comprise administering a first terpene. In one embodiment, the first terpene is a purified first terpene.
[00158] As used here, the term "terpene" refers to a compound that belongs to a large class of compounds often biosynthesized from 5-carbon isoprene units. In one embodiment, a terpene is produced by a variety of plants, for example, conifers, cannabis, basil, etc. In one embodiment, a terpene is produced by an insect, for example, termites or swallowtail butterflies. In one embodiment, a terpene is a volatile compound. In one embodiment, a terpene produces
Petition 870190082150, of 22/08/2019, p. 37/121
36/99 an odor. In one embodiment, a terpene is a major component of a natural resin, for example, terenbintin produced from resin. In one embodiment, a terpene is biosynthetically derived from isoprene units, which have the molecular formula CsHs. In one embodiment, the molecular formula of terpenes is a multiple of (CsHsJn, where n is the number of bound isoprene units.
[00159] In the context of this description, when a terpene is modified chemically, such as by oxidation or rearrangement of the carbon skeleton, the resulting compound is referred to as a terpenoid. In the relevant state of the art, terpenoids are sometimes referred to as isoprenoids.
[00160] In one embodiment, a terpene is the primary constituent or constituents of an essential oil from a plant and / or flower. Essential oils are widely used as fragrances in perfumery, medicine and alternative medicines, for example, aromatherapy.
[00161] In one embodiment, a terpene is categorized according to the number of isoprene units (CsHs) in the compound, for example, a monoterpene (CioHe), a sesquiterpene (C15H24), a diterpene (C20H32), a triterpene (C30H48), or a tetraterpene (C10H64).
[00162] In one embodiment, a first purified terpene is chosen from acetanisol, acetyl cedrene, anethole, anisol, benzaldehyde, bornyl acetate, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, alpha-caryophyllene, beta-caryophyllene, caryophyllene oxide, cedene, cedene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, cinnamic acid, citronelal, citronelol, cimene, eicosano, elemene, estragol, ethyl acetate, cinamate ethyl, ethyl maltol, eucalyptol / 1,8-cineol, eudesmol, eugenol, eufol, farnesene, farnesol, fenchone, geraniol, geranyl acetate, guaia-1 (10), 11-diene, guaiacol, guaiol, guaiene, gurjunene, herniarin, hexanaldehyde, hexanoic acid,
Petition 870190082150, of 22/08/2019, p. 12/38
37/99 humulene, ionone, ipsdienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomircenol, isoprene, isopulegol, isovaleric acid, lavandulol, limonene, gamma-linolenic acid, linalool, longifolene, lycopene, menthol, methyl butyrate 3-mercapto-2-methylpentanal, beta-mercaptoethanol, mercaptoacetic acid, methyl salicylate, methylbutenol, methyl-2-methylvalerate, methyl thiobutyrate, beta-myrcene, gamma-muurolene, nepetalactone, nerol, nerolidine, nerolidol, nanaldehyde, acetate , nonanoic acid, ocimene, octanal, octanoic acid, pentyl butylate, felandrene, phenylacetaldehyde, phenylacetic acid, phenylethanethiol, phytol, pinene, propanothiol, pristimerin, pulegone, retinol, rutin, sabinene, squalene, taxadene, terpine, terpine, terpine, terpine, terpine, terpine, terpine, terpine ol, terpinolene, tuiona, thymol, umbeliferone, undecanal, verdoxan or vanillin.
[00163] In one embodiment, a first purified terpene is chosen from among bornyl acetate, alpha-bisabolol, borneol, camphene, camphor, carene, beta-karyophylene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene , fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, beta-myrcene, nerolidol, ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[00164] As used here, the term bornyl acetate refers to a compound with the following structural formula:
/ [00165] In the context of this description, the term “bornyl acetate” includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of bornyl acetate and a first psilocybin derivative. In a
Petition 870190082150, of 22/08/2019, p. 12/31
38/99, the compositions and methods described in this document comprise administering a formulation of purified bornyl acetate and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of bornyl acetate and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified bornyl acetate and a first derivative of purified psilocybin.
[00166] As used here, the term alpha-bisabolol refers to a compound with the following structural formula:
[00167] In the context of this description, the term "alpha-bisabolol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering an alpha-bisabolol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified alpha-bisabolol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering an alpha-bisabolol formulation and a purified psilocybin first derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified alpha-bisabolol and a first derivative of purified psilocybin.
[00168] As used here, the term “borneol” refers to a compound
Petition 870190082150, of 22/08/2019, p. 40/121
39/99 with the following structural formula:
ÓH [00169] In the context of this description, the term “borneol” includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of borneol and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified borneol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of borneol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified borneol and a first derivative of purified psilocybin.
[00170] As used here, the term camphene refers to a compound with the following structural formula:
[00171] In the context of this description, the term camphene includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and
Petition 870190082150, of 22/08/2019, p. 41/121
40/99 methods described in this document comprise administering a camphene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified camphene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of camphene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified camphene and a first derivative of purified psilocybin.
[00172] As used herein, the term "camphor" refers to a compound with one of the following structural formulas:
[00173] In the context of this description, the term "camphor" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a camphor formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified camphor formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a camphor formulation and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified camphor formulation and a first purified psilocybin derivative.
Petition 870190082150, of 22/08/2019, p. 42/121
41/99 [00174] As used here, the term careno refers to a compound with the following structural formula:
[00175] In the context of this description, the term carene includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of carene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified carene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of carene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified carene and a first derivative of purified psilocybin.
[00176] As used here, the term beta-karyophylene refers to a compound with the following structural formula:
H j [00177] In the context of this description, the term beta-karyophylene comprises any derivative and / or another, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of beta-karyophylene and a first psilocybin derivative. In one embodiment,
Petition 870190082150, of 22/08/2019, p. 43/121
42/99 the compositions and methods described in this document comprise administering a purified beta-karyophylene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of beta-karyophylene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a purified beta-karyophylene formulation and a first purified psilocybin derivative.
[00178] As used here, the term cedrene refers to a compound with any of the following structural formulas:
[00179] In the context of this description, the term cedreno includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of cedrene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified cedrene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of cedrene and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified cedrene and a first purified psilocybin derivative.
[00180] As used here, the term cymene refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 44/121
43/99
j £ h ₅ [00181] In the context of this description, the term "cimene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a cymene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified chymen formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a cymene formulation and a purified psilocybin first derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified chymen formulation and a purified psilocybin first derivative.
[00182] As used here, the term element refers to a compound with the following structural formula:
[00183] In the context of this description, the term elemene includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a
Petition 870190082150, of 22/08/2019, p. 45/121
44/99 formulation of elemene and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified element and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering an elemene formulation and a purified psilocybin first derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified elemene formulation and a purified psilocybin first derivative.
[00184] As used here, the term eucalyptol refers to a compound with the following structural formula:
[00185] In the context of this description, the term "eucalyptol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of eucalyptol and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified eucalyptol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of eucalyptol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified eucalyptol and a first derivative of purified psilocybin.
[00186] As used here, the term eudesmol refers to a compound
Petition 870190082150, of 22/08/2019, p. 46/121
45/99 with any of the following structural formulas:
[00187] In the context of this description, the term "eudesmol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of eudesmol and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified eudesmol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of eudesmol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified eudesmol and a first derivative of purified psilocybin.
[00188] As used here, the term farnesene refers to a compound with the following structural formula:
[00189] In the context of this description, the term "farnesene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a farnesene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise
Petition 870190082150, of 22/08/2019, p. 47/121
46/99 administer a formulation of purified farnesene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of farnesene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified farnesene and a first derivative of purified psilocybin.
[00190] As used here, the term fenchol refers to a compound with the following structural formula:

[00191] In the context of this description, the term fenchol includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a fenchol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified fenchol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a fenchol formulation and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified fenchol formulation and a purified psilocybin first derivative.
[00192] As used here, the term geraniol refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 48/121
47/99 [00193] In the context of this description, the term geraniol includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof.
[00194] In one embodiment, the compositions and methods described in this document comprise administering a geraniol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified geraniol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a geraniol formulation and a purified psilocybin first derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified geraniol and a first derivative of purified psilocybin.
[00195] As used here, the term guaiacol refers to a compound with the following structural formula:
'3 [00196] In the context of this description, the term guaiacol includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of guaiacol and a first psilocybin derivative. In a form of
Petition 870190082150, of 22/08/2019, p. 49/121
48/99 embodiment, the compositions and methods described in this document comprise administering a formulation of purified guaiacol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of guaiacol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified guaiacol and a first derivative of purified psilocybin.
[00197] As used here, the term humulene refers to a compound with the following structural formula:

[00198] In the context of this description, the term "humulene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a humulene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified humulene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a humulene formulation and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified humulene and a first derivative of purified psilocybin.
[00199] As used here, the term isoborneol refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 50/121
49/99
[00200] In the context of this description, the term "isoborneol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering an isoborneol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified isoborneol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering an isoborneol formulation and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified isobornol formulation and a purified psilocybin first derivative.
[00201] As used here, the term limonene refers to a compound with the following structural formula:
I

[00202] In the context of this description, the term "limonene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a
Petition 870190082150, of 22/08/2019, p. 51/121
50/99 formulation of limonene and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified limonene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of limonene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified limonene and a first derivative of purified psilocybin.
[00203] As used here, the term "linalool" refers to a compound with the following structural formula:
[00204] In the context of this description, the term "linalool" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a linalool formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified linalool and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of linalool and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified linalool and a first derivative of purified psilocybin.
[00205] As used here, the term menthol refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 52/121
51/99
[00206] In the context of this description, the term menthol includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of menthol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified menthol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of menthol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified menthol and a first derivative of purified psilocybin.
[00207] As used here, the term beta-myrcene refers to a compound with the following structural formula:
[00208] In the context of this description, the term "beta-myrcene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of beta-myrcene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise
Petition 870190082150, of 22/08/2019, p. 53/121
52/99 administer a formulation of purified beta-mycrene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of beta-myrcene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified beta-mycrene and a first derivative of purified psilocybin.
[00209] As used here, the term nerolidol refers to a compound with the following structural formula:
[00210] In the context of this description, the term nerolidol includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a nerolidol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified nerolidol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of nerolidol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified nerolidol and a first derivative of purified psilocybin.
[00211] As used here, the term "ocimene" refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 54/121
53/99 [00212] In the context of this description, the term "ocimene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering an ocimene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified ocimene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering an ocimene formulation and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified ocimene formulation and a purified psilocybin first derivative.
[00213] As used here, the term felandrene refers to a compound with the following structural formula:
[00214] In the context of this description, the term felandrene includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a felandrene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified felandrene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a felandren formulation and a first
Petition 870190082150, of 22/08/2019, p. 55/121
54/99 purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified felandrene and a first derivative of purified psilocybin.
[00215] As used here, the term phytol refers to a compound with the following structural formula:
OH [00216] In the context of this description, the term "phytol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a phytol formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified phytol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of phytol and a first purified psilocybin derivative.
In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified phytol and a first derivative of purified psilocybin.
[00217] As used here, the term pinene refers to a compound with the following structural formula:
[00218] In the context of this description, the term pinene includes any derivative and / or salt thereof, including any isomeric, structural variations
Petition 870190082150, of 22/08/2019, p. 56/121
55/99 and / or enantiomeric of the same. In one embodiment, the compositions and methods described in this document comprise administering a pinene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified pinene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of pinene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified pinene and a first derivative of purified psilocybin.
[00219] As used here, the term pulegone refers to a compound with the following structural formula:
_z ------ çh ₃ chY <
A-- 'W ₃ [00220] In the context of this description, the term "pulegone" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of pulegone and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified pulegone formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of pulegone and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a purified pulegone formulation and a purified psilocybin first derivative.
[00221] As used here, the term sabinene refers to a compound
Petition 870190082150, of 22/08/2019, p. 57/121
56/99 with the following structural formula:
CHs [00222] In the context of this description, the term "sabinene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of sabinene and a first derivative of psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified sabinene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of sabinene and a first derivative of purified psilocybin. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified sabinene and a first derivative of purified psilocybin.
[00223] As used here, the term terpineol refers to a compound with the following structural formula:
[00224] In the context of this description, the term "terpineol" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a terpineol formulation and a first psilocybin derivative. In a form of
Petition 870190082150, of 22/08/2019, p. 58/121
In this embodiment, the compositions and methods described in this document comprise administering a formulation of purified terpineol and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of terpineol and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified terpineol and a first derivative of purified psilocybin.
[00225] As used here, the term terpinolene refers to a compound with the following structural formula:
[00226] In the context of this description, the term "terpinolene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a terpinolene formulation and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified terpinolene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of terpinolene and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified terpinolene and a first derivative of purified psilocybin.
[00227] As used here, the term valencene refers to a compound with the following structural formula:
Petition 870190082150, of 22/08/2019, p. 59/121
58/99
I [00228] In the context of this description, the term "valencene" includes any derivative and / or salt thereof, including any isomeric, structural and / or enantiomeric variations thereof. In one embodiment, the compositions and methods described in this document comprise administering a formulation of valencene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified valencene and a first psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of valencene and a first purified psilocybin derivative. In one embodiment, the compositions and methods described in this document comprise administering a formulation of purified valencene and a first derivative of purified psilocybin.
[00229] In one embodiment, the compositions described in this document comprise a specific ratio (e.g., a molar ratio) of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified terpene .
[00230] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified terpene .
[00231] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the
Petition 870190082150, of 22/08/2019, p. 60/121
59/99 first purified terpene.
[00232] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified terpene .
[00233] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified terpene .
[00234] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified terpene .
[00235] In one embodiment, the compositions and methods described in this document comprise a first purified psilocybin derivative, a first purified cannabinoid, and a first purified terpene.
[00236] In one embodiment, the compositions described in this document comprise a specific ratio (e.g., a molar ratio) of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified terpene.
[00237] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 75: 1 to about 1:75 between the first psilocybin derivative
Petition 870190082150, of 22/08/2019, p. 61/121
60/99 purified and the first purified terpene.
[00238] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified terpene.
[00239] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified terpene.
[00240] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified terpene.
[00241] In one embodiment, the compositions described in this document comprise a specific ratio (for example, a molar ratio) of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified cannabinoid and a specific ratio (for example, a molar ratio of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified terpene.
[00242] In one embodiment, a first purified terpene modulates the activity of a neurotransmitter activity modulator, for example, a
Petition 870190082150, of 22/08/2019, p. 62/121
61/99 serotonergic drug, adrenergic drug, dopaminergic drug, psilocybin derivative, etc.
[00243] As used here, the term serotonergic drug refers to a compound that binds, blocks or otherwise influences (for example, through an allosteric reaction) the activity of a serotonin receptor. In one embodiment, a serotonergic drug binds to a serotonin receptor. In one embodiment, a serotonergic drug indirectly affects a serotonin receptor, for example, through interactions that affect the reactivity of other molecules at the serotonin receptor. In one embodiment, a serotonergic drug is an agonist, for example, a compound that activates a serotonin receptor. In one embodiment, a serotonergic drug is an antagonist, for example, a compound that binds, but does not activate, a serotonin receptor, for example, blocking a receptor. In one embodiment, a serotonergic drug is an effector molecule, for example, a compound that binds to an enzyme for allosteric regulation. In one embodiment, a serotonergic drug acts (directly or indirectly) on more than one type of receptor (for example, 5HT, dopamine, adrenergic, acetylcholine, etc.).
[00244] In one embodiment, a serotonergic drug is an antidepressant.
[00245] In one embodiment, a serotonergic drug is an anxiolytic.
[00246] 3In one embodiment, a serotonergic drug is a selective serotonin reuptake inhibitor.
[00247] In one embodiment, a serotonergic drug is a selective serotonin and norepinephrine reuptake inhibitor.
[00248] Some examples of serotonergic drugs include the following molecules: 6-allyl-N, N-diethyl-NL, N, N-dibutyl-T, N, N-diethyl-T, N, N-diisopropyl-T, 5
Petition 870190082150, of 22/08/2019, p. 63/121
62/99 methoxy-alpha-methyl-T, N, N-dimethyl-T, 2, alpha-dimethyl-T, alpha, N-dimethyl-T, N, N-dipropyl-T, Netyl-N-isopropyl-T , alpha-ethyl-T, 6, N, N-Triethyl-NL, 3,4-dihydro-7-methoxy-1-methyl-C, 7methoxy-1-methyl-C, N, N-dibutyl-4 -hydroxy-T, N, N-diethyl-4-hydroxy-T, N, N-diisopropyl-4hydroxy-T, N, N-dimethyl-4-hydroxy-T, N, N-dimethyl-5-hydroxy-T , N, N-dipropyl-4-hydroxy-T, Netyl-4-hydroxy-N-methyl-T, 4-hydroxy-N-isopropyl-N-methyl-T, 4-hydroxy-N-methyl-N-propyl -T, 4-hydroxy-N, N-tetramethylene-T Ibogaine, N, N-diethyl-L, N-butyl-N-methyl-T, N, N-diisopropyl4,5-methylenedioxy-T, N, N-diisopropyl- 5,6-methylenedioxy-T, N, N-dimethyl-4,5methylenedioxy-T, N, N-dimethyl-5,6-methylenedioxy-T, N-lsopropyl-N-methyl-5,6methylenedioxy-T, N, N-diethyl-2-methyl-T, 2, N, N-trimethyl-T, N-acetyl-5-methoxy-T, N, N-diethyl-5-methoxy-T, N, N-diisopropyl-5-methoxy- T, 5-methoxy-N, N-dimethyl-T, N-isopropyl-4-methoxy-Nmethyl-T, N-isopropyl-5-methoxy-N-methyl-T, 5,6-dimethoxy-N-isopropyl- N-methyl-T, 5-methoxyN-methyl-T, 5-methoxy-N, N-tetramethylene-T, 6-methoxy-1-methyl-1,2,3, 4-tetrahydro-C, 5methoxy-2, N, N-trimethyl-T, N, N-dimethyl-5-methylthio-T, N-isopropyl-N-methyl-T, alpha-methyl-T, Netyl-T, N-methyl-T, 6-Propyl-NL, N, N-tetramethylene-T, tryptamine, and 7-methoxy-1-methyl1,2,3,4-tetrahydro-C, alpha, N-dimethyl-5-methoxy -T. For additional information on these compounds, see Shulgin, AT & Shulgin, A. (2016). Tihkal: The Continuation. Berkeley, CA: Transform Press.
[00249] In one embodiment, a serotonergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, chlordiazepoxide, citalopram, clonazepam, chloxamide, diazoxamide, chlamydexamide, diazoxamide, chlamydexamide, diazoxamide, chlamydexamide, diazamide. , fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4-methylenedioxymethamphetamine, milnacipran, mirtazapine, naratriptan, paroxetine, pethidine, phenethylamine, psycho, oxazepam, seramine, serboxetine, serboxetine, serboxetine, serboxetine, serboxetine, serboxetine, serine, trine a tryptamine, venlafaxine, vortioxetine and / or derivatives thereof.
[00250] As used here, the term “serotonin” refers to a
Petition 870190082150, of 22/08/2019, p. 64/121
63/99 neurotransmitter compound with the following structural formula: H n H
[00251] In one embodiment, serotonin acts on a serotonin receptor, for example, by acting as a ligand to a 5-HT receptor. In one embodiment, serotonin is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions described in this document increase the activity at a serotonin receptor. In one embodiment, the compositions described in this document decrease the activity at a serotonin receptor.
[00252] As used here, the term serotonin receptor refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways resulting in a cellular response. In one embodiment, a serotonin receptor is found in a cell within an organism's central nervous system. In one embodiment, a serotonin receptor is found in a cell within an organism's peripheral nervous system. In one embodiment, serotonin is the natural ligand for a serotonin receptor. In one embodiment, a serotonin receptor modulates the release of a neurotransmitter, for example, glutamate, gamma-aminobutyric acid, dopamine, epinephrine (also norepinephrine), acetylcholine, etc. In one embodiment, a serotonin receptor modulates the release of a hormone, for example, oxytocin, prolactin, vasopressin, cortisol, corticotropin, substance P, etc.
[00253] Examples of serotonin receptors include, but are not limited to 5-HTia, 5-HTib, 5-HTid, 5-HTi _and , 5-ΗΤν, 5-HT2A, 5-HT2B, 5-HT2C, 5 -HT3, 5
Petition 870190082150, of 22/08/2019, p. 65/121
64/99
HT ₄ , 5-HTsa, 5-HTsb, 5-ΗΤθ, and 5-HT ₇ .
[00254] As used here, the term adrenergic drug refers to a compound that binds, blocks or otherwise influences (for example, through an allosteric reaction) the activity of an adrenergic receptor. In one embodiment, an adrenergic drug binds to an adrenergic receptor. In one embodiment, an adrenergic drug indirectly affects an adrenergic receptor, for example, through interactions that affect the reactivity of other molecules in the adrenergic receptor. In one embodiment, an adrenergic drug is an agonist, for example, a compound that activates an adrenergic receptor. In one embodiment, an adrenergic drug is an antagonist, for example, a compound that binds, but does not activate, an adrenergic receptor, for example, blocking a receptor. In one embodiment, an adrenergic drug is an effector molecule, for example, a compound that binds to an enzyme for allosteric regulation. In one embodiment, an adrenergic drug acts (directly or indirectly) on more than one type of receptor (eg, 5HT, dopamine, adrenergic, acetylcholine, etc.).
[00255] In one embodiment, an adrenergic drug is an antidepressant.
[00256] In one embodiment, an adrenergic drug is a norepinephrine transporter inhibitor.
[00257] In one embodiment, an adrenergic drug is an inhibitor of the vesicular monoamine transporter.
[00258] In one embodiment, an adrenergic drug is chosen from among adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepine, duloxetine, smirtazpine, mianserine, mirabegron, mirtazapine, norepinephrine, phenorepinephrine, norepinephrine, phenorephrine, piperine, piperine reserpine, ritodrine, setiptyline, tesofensina, timolol, trazodone, trimipramine or xylazine.
Petition 870190082150, of 22/08/2019, p. 66/121
65/99 [00259] As used here, the term adrenaline, also known as epinephrine, refers to a neurotransmitter compound with the following structural formula:
OH
[00260] In one embodiment, adrenaline acts on an adrenergic receptor, for example, acting as a ligand on an adrenergic receptor. In one embodiment, adrenaline is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions described in this document increase the activity at an adrenergic receptor. In one embodiment, the compositions described in this document decrease activity at an adrenergic receptor.
[00261] As used here, the term adrenergic receptor refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways leading to a cellular response. In one embodiment, an adrenergic receptor is found in a cell within an organism's central nervous system. In one embodiment, an adrenergic receptor is found in a cell within an organism's sympathetic nervous system.
[00262] Examples of adrenergic receptors include, but are not limited to, cuA, cuB, cuD, O2A, O2B, O2C, βι, β2 and β3.
[00263] As used here, the term norepinephrine refers to a neurotransmitter compound with the following structural formula:
OH
Petition 870190082150, of 22/08/2019, p. 67/121
66/99 [00264] In one embodiment, norepinephrine acts on an adrenergic receptor, for example, by acting as a ligand on an adrenergic receptor. In one embodiment, norepinephrine is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions described in this document increase the activity at an adrenergic receptor. In one embodiment, the compositions described in this document decrease activity at an adrenergic receptor.
[00265] As used here, the term dopaminergic drug refers to a compound that binds, blocks or otherwise influences (for example, through an allosteric reaction) the activity at a dopamine receptor. In one embodiment, a dopaminergic drug binds to a dopamine receptor. In one embodiment, a dopaminergic drug indirectly affects a dopamine receptor, for example, through interactions that affect the reactivity of other molecules at the dopamine receptor. In one embodiment, a dopaminergic drug is an agonist, for example, a compound that activates a dopamine receptor. In one embodiment, a dopaminergic drug is an antagonist, for example, a compound that binds, but does not activate, a dopamine receptor, for example, blocking a receptor. In one embodiment, a dopaminergic drug is an effector molecule, for example, a compound that binds an enzyme for allosteric regulation. In one embodiment, a dopaminergic drug acts (directly or indirectly) on more than one type of receptor (for example, 5HT, dopamine, adrenergic, acetylcholine, etc.).
[00266] In one embodiment, a dopaminergic drug is an inhibitor of the dopamine transporter.
[00267] In one embodiment, a dopaminergic drug is an inhibitor of the vesicular monoamine transporter.
[00268] In one embodiment, a dopaminergic drug is
Petition 870190082150, of 22/08/2019, p. 68/121
67/99 chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanilenine, phenamine, phemoline, pemoline , pimozide, pyribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine or thioridazine.
[00269] As used here, the term dopamine refers to a neurotransmitter compound with the following structural formula:
[00270] In one embodiment, dopamine acts on a dopamine receptor, for example, acting as a ligand on a dopamine receptor. In one embodiment, dopamine is produced by an organism for use as a neurotransmitter within that organism. In one embodiment, the compositions described in this document increase the activity at a dopamine receptor. In one embodiment, the compositions described in this document decrease the activity at a dopamine receptor.
[00271] As used here, the term "dopamine receptor" refers to a collection of proteins outside a cell capable of receiving signals and activating internal signal transduction pathways resulting in a cellular response. In one embodiment, a dopamine receptor is found in a cell within an organism's central nervous system.
[00272] Examples of dopamine receptors include, but are not limited to Di, D2, D2Sh, D2i_h, D3, D4 and Ds.
[00273] In one embodiment, a purified first terpene modulates the activity of a neurotransmitter at its native receptor, for example, serotonin
Petition 870190082150, of 22/08/2019, p. 69/121
68/99 at a serotonin receptor, dopamine at a dopaminergic receptor, norephedrine at an adrenergic receptor, etc.
[00274] In one embodiment, a purified first terpene is active on one or more receptors, for example, a serotonin receptor, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycinergic receptor.
[00275] In one embodiment, the methods and compositions described in this document comprise an excipient.
[00276] As used here, the term "excipient" refers to a compound useful in increasing the bioavailability of an active ingredient or ingredients. In one embodiment, an excipient allows for faster absorption of an active ingredient in a human body. In one embodiment, an excipient binds to a compound, thereby providing faster permeability through membranes, barriers, walls, etc. In one embodiment, the methods described in this document comprise administering two or more excipients, for example, a pH buffer, an antioxidant, etc. In one embodiment, an excipient also functions as a stabilizer. In one embodiment, an excipient binds to two or more compounds forming a homogeneous mixture within a solution, for example, a water-insoluble purified compound (for example, a cannabinoid or terpene) and a purified psilocybin derivative ( soluble in water) forming a homogeneous mixture in water.
[00277] Examples of excipients are, but are not limited to, sodium lauryl sulfate, sucrose, alcohol, gelatin, polyvinylpyrrolidone, methionine, Vitamin E TPGS, dimethyl sulfoxide, tartrazine, polyethylene glycol, magnesium stearate, stearic acid, smoked silica, talc , magnesium carbonate or benzalkonium chloride.
[00278] In one embodiment, the compositions described in this
Petition 870190082150, of 22/08/2019, p. 70/121
69/99 document comprises a monoamine oxidase inhibitor.
[00279] As used herein, the term monoamine oxidase inhibitor refers to a molecule binding to a monoamine oxidase enzyme, which therefore reduces the activity of the monoamine oxidase enzyme. In the context of this description, examples of monoamine oxidase inhibitors include aurorix, deprenyl, eldepril, emsam, humoril, hydracarbazine, isocarboxazide, linezolid, manerix, nidrazide, phenelzine, pyrazidol, procarbazine, rasagiline and tranylcpromine. In one embodiment, monoamine oxidase catalyzes the oxidation of a monoamine, for example, serotonin, dopamine, norepinephrine, amphetamine, adrenaline, etc.
[00280] In one embodiment, the methods and compositions disclosed herein comprise a stabilizer.
[00281] As used here, the term "stabilizer" refers to a compound useful in preventing the degradation of an active ingredient, for example, a psilocybin derivative, a cannabinoid, a terpene, etc. In one embodiment, a stabilizer prevents a first psilocybin derivative from degrading. In one embodiment, a stabilizer prevents a first psilocybin derivative from reacting with other compounds in the composition, for example, a cannabinoid, a terpene, a base, an acid, etc. In one embodiment, a stabilizer prevents a first psilocybin derivative from reacting with the ambient atmosphere, for example, heat, light, water and / or oxygen. In one embodiment, a stabilizer comprises an antioxidant. In one embodiment, a stabilizer comprises a pH buffer.
[00282] In one embodiment, the methods and compositions described in this document comprise an antioxidant.
[00283] As used herein, the term antioxidant refers to a compound and / or composition useful in preventing oxidation. In one embodiment, an antioxidant protects an active ingredient from "free radicals". At the
Petition 870190082150, of 22/08/2019, p. 71/121
In the context of this description, a “free radical” is an atom, molecule or an ion with an unpaired valence electron. In one embodiment, an antioxidant is an electron donor.
[00284] In one embodiment, an antioxidant is chosen from ascorbic acid, lycopene, tocopherol, melatonin, retinol, astaxanthin, lutein, apigenin, carnosine, selenium, zinc, cucurmine, and / or a salt or derivative thereof.
[00285] In one embodiment, an antioxidant is ascorbic acid and / or salts or derivatives thereof. In the context of this description, the term "ascorbic acid" includes Vitamin C and / or a salt or derivative thereof.
[00286] In one embodiment, an antioxidant prevents oxidation of a composition comprising one or more compounds described in this document, for example, derivatives of psilocybin, cannabinoids, terpenes and / or mixtures thereof. For example, preventing oxidation of a phenolic group attached to a psilocybin derivative.
[00287] As used here, the term oxidation refers to the formal loss of electrons and / or the increase in the state of formal oxidation and / or the addition of an atom or atoms of oxygen. Reduction refers to the formal gain of electrons and / or the decrease in the state of formal oxidation. Zumdahl, Steven S., et al. Chemistry, 7th. Cengage Learning, 2018.
[00288] In one embodiment, an antioxidant prevents oxidation of a composition comprising one or more compounds described in this document, for example, psilocybin derivatives or mixtures thereof.
[00289] In one embodiment, the methods and compositions described in this document comprise a pH buffer.
[00290] As used herein, the term pH buffer refers to a compound or composition useful in maintaining the pH of a composition. In one embodiment, a pH buffer comprises a weak acid and a base
Petition 870190082150, of 22/08/2019, p. 72/121
Corresponding 71/99 conjugate. In one embodiment, a pH buffer comprises a weak base and a corresponding conjugated acid. In one embodiment, a pH buffer does not alter the pH of a composition with the addition of a strong acid and / or base.
[00291] In one embodiment, a pH buffer maintains the pH of a composition around 7.
[00292] In one embodiment, a pH buffer maintains the pH of a composition below 7.
[00293] In one embodiment, a pH buffer maintains the pH of a composition above 7.
[00294] In one embodiment, a pH buffer maintains the pH of a composition between 2-6.
[00295] In one embodiment, a pH buffer maintains the pH of a composition between 5-7.
[00296] In one embodiment, a pH buffer maintains the pH of a composition between 6-8.
[00297] In one embodiment, a pH buffer maintains the pH of a composition between 7-10.
[00298] In one embodiment, a pH buffer comprises citric acid, acetic acid, monosodium phosphate, N-cyclohexyl-2aminoethanesulfonic acid, borate, hydrochloric acid and / or sodium hydroxide.
[00299] In one embodiment, the methods described in this document comprise administering a formulation comprising an acid.
[00300] As used here, the term acid refers to a molecule or ion capable of donating a proton, that is, H ⁺ , and / or accepting electrons. In one embodiment, an acid refers to a Lewis acid. In one embodiment, an acid refers to a Bronsted acid. In one embodiment, an acid
Petition 870190082150, of 22/08/2019, p. 73/121
72/99 is determined by a pH of the compositions. In one embodiment, a pH below 7 indicates the presence of an acid.
[00301] In one embodiment, the compositions and methods described in this document comprise administering a formulation comprising a base.
[00302] As used here, the term "base" refers to a molecule or ion capable of accepting a proton, that is, an H ⁺ . In one embodiment, a "base" refers to a molecule capable of donating a pair of electrons, that is, a Lewis base. In one embodiment, the presence of a base is determined by the pH of a compound. In one embodiment, a pH above 7 indicates the presence of a base.
[00303] In one embodiment, the compositions and methods described in this document comprise administering a water-soluble composition.
[00304] As used here, the term water-soluble refers to a compound capable of dissolving in water at standard temperature and pressure. In one example, 1 g of a compound dissolves in 1 L of water. In one example, 2 g of a compound dissolves in 1 L of water. In one example, 5 g of a compound dissolves in 1 L of water. In one example, 10 g of a compound dissolves in 1 L of water. In one embodiment, the solubility of a compound in water is an inherent property of a compound. In one embodiment, the solubility of a compound in water is facilitated by another compound, for example, an excipient.
[00305] In one embodiment, the compositions and methods described in this document comprise a solvent.
[00306] As used here, the term solvent refers to a compound or composition that dissolves another (a solute), thus creating a solution. In one embodiment, the solvent is water. In one embodiment, the solvent is a
Petition 870190082150, of 22/08/2019, p. 74/121
73/99 oil. In one embodiment, the solvent is an alcohol.
[00307] In one embodiment, the compositions and methods described in this document comprise administering a first purified psilocybin derivative present as and / or within a homogeneous mixture in a first dosage formulation.
[00308] In one embodiment, the compositions and methods described in this document comprise administering a first purified psilocybin derivative present as and / or within a homogeneous mixture in a first dosage formulation.
[00309] In one embodiment, the compositions and methods described in this document comprise administering a first purified psilocybin derivative and a first purified terpene present as and / or within a homogeneous mixture in a first dosage formulation.
[00310] In one embodiment, the compositions and methods described in this document comprise administering a first purified psilocybin derivative, a first purified cannabinoid, and a first purified terpene present as and / or within a homogeneous mixture in a first formulation of dosage.
[00311] In one embodiment, the compositions and methods described in this document comprise administering a first purified psilocybin derivative, a first purified cannabinoid, a first purified terpene, and an excipient present as and / or within a homogeneous mixture in a first dosage formulation.
[00312] As used here, the term homogeneous mixture refers to a solid, liquid or gaseous composition that has two or more compounds present in a state or element, for example, a clear and colorless solution. In one embodiment, the homogeneous mixtures described in this document present
Petition 870190082150, of 22/08/2019, p. 75/121
74/99 the same proportion, concentration and / or ratio of its components in different samples. In one embodiment, the components in the homogeneous mixture are in the same state of matter. In one embodiment, a homogeneous mixture comprises one or more compounds in a solution, for example, a first psilocybin derivative and a first cannabinoid in a clear solution. In one embodiment, the compositions described in this document are present as a homogeneous mixture, for example, a solution without particles, a solution with equal concentrations between the samples, a powder of similar particle size, etc.
[00313] In one embodiment, a homogeneous mixture is a solution comprising a first purified psilocybin derivative.
[00314] In one embodiment, a homogeneous mixture is a solution comprising a first purified psilocybin derivative and a first purified cannabinoid.
[00315] In one embodiment, a homogeneous mixture is a solution comprising a first purified psilocybin derivative and a first purified terpene.
[00316] In one embodiment, a homogeneous mixture is a solution comprising a first purified psilocybin derivative, a first purified cannabinoid and a first purified terpene.
[00317] In one embodiment, a homogeneous mixture has little or no deviation in a chemical composition between the different samples taken from the compositions described in this document.
[00318] As used here, the phrase little or no deviation means that different samples of the same composition are internally consistent. For example, two different 1 g aliquots taken from the same 100 g sample would have little or no deviation since they share substantially the
Petition 870190082150, of 22/08/2019, p. 76/121
75/99 same chemical composition when characterized by chromatography and / or spectrometry. On the other hand, fruiting bodies of naturally occurring fungi (also known as mushrooms) or plants often show a considerable deviation in the concentration of certain compounds.
[00319] For example, the concentration of psilocybin and / or psilocin varies widely among naturally occurring fungi fruiting body species, for example, 0 to 15 mg of psilocybin and / or psilocin per gram of dry plant material. Stafford, Peter. Psychedelics Encyclopedia: Third Expanded Edition. Ronin Publishing, 1993. Likewise, extracts extracted from these highly variable samples are similarly variable.
[00320] The concentration of psilocybin and / or psilocin varies greatly between species and even between specimens of a species collected and / or cultivated from the same culture. Bigwood J, Beug MW (1982). Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer ”. Journal of Ethnopharmacology. 5 (3): 287-91.
[00321] In addition, concentrations of molecules in different samples may change at different rates due to degradation, such as oxidative degradation and / or enzymatic degradation.
[00322] As an advance beyond the state of the art, the methods described in this document include managing compositions that show little or no deviation between the rates collected from a given batch. In one embodiment, a sample composition weighing 100 grams, each 1 gram portion has a chemical concentration deviation of less than about 10% compared to the technology currently available. In another embodiment, a sample weighing 100 grams, each 1 gram portion has a deviation in chemical concentration of less than about 5%, compared to the technology currently available. In another embodiment, a sample weighing 100
Petition 870190082150, of 22/08/2019, p. 77/121
76/99 grams, each 1 gram portion would have a deviation in chemical concentration of less than 1%, compared to the technology currently available.
[00323] In one embodiment, the compositions and methods described in this document comprise a dephosphorylating agent.
[00324] As used herein, the term "dephosphorylating agent" refers to a compound or composition capable of facilitating the removal of a phosphate group from a molecule comprising a phosphate group. In one embodiment, a dephosphorylating agent is kept physically separate (for example, a film, coating or other barrier that prevents mixing) from an active ingredient, for example, a purified psilocybin derivative within a composition. In one embodiment, a dephosphorylating agent removes a phosphate group from a psilocybin derivative, for example, psilocybin.
[00325] In one embodiment, the methods described in this document comprise dephosphorylation of a psilocybin derivative.
[00326] As used here, the term dephosphorylation refers to the removal of a phosphate group from a molecule with a phosphate group. In one embodiment, dephosphorylating a first purified psilocybin derivative comprises cleaving the chemical bonds through hydrolysis. In one embodiment, dephosphorylating a first purified psilocybin derivative alters (for example, increases) the activity of at one or more neurotransmitter receptors. In one embodiment, dephosphorylation of a first purified psilocybin derivative occurs within an organism. In one embodiment, dephosphorylation of a first purified psilocybin derivative occurs before administration of a composition.
[00327] This document describes a method of modulating activity in a neurotransmitter receptor, which comprises: administering a modulator of neurotransmitter activity; and
Petition 870190082150, of 22/08/2019, p. 78/121
77/99 administering a first dosage formulation comprising a first purified psilocybin derivative to the subject in need of treatment, wherein the first dosage formulation modulates activity at a neurotransmitter receptor.
[00328] As used here, the term "modulate the activity of the neurotransmitter activity modulator" refers to the alteration, manipulation and / or adjustment of the ability of a compound or composition to affect a neurotransmitter receptor. In one embodiment, modulating the activity of a neurotransmitter activity modulator comprises administering an agonist to a neurotransmitter receptor. In one embodiment, modulating the activity of a neurotransmitter activity modulator comprises administering an antagonist to a neurotransmitter receptor.
[00329] As used herein, the term administer (for example, administer a drug) refers to dosage, treatment, giving and / or providing. In one embodiment, administering a neurotransmitter activity modulator comprises providing a neurotransmitter activity modulator to an organism with a neurotransmitter receptor, for example, a human. In one embodiment, administering a neurotransmitter activity modulator comprises providing a neurotransmitter activity modulator together with a purified psilocybin derivative, for example, a formulation containing each of a neurotransmitter activity modulator and a purified psilocybin derivative in one dosage. only. In one embodiment, administering a neurotransmitter activity modulator comprises applying a transdermal composition, for example, applying a topical composition to the skin containing each of a neurotransmitter activity modulator and a purified psilocybin derivative. In one embodiment, administering a neurotransmitter activity modulator comprises giving a transmucosal preparation, for example, providing a pill
Petition 870190082150, of 22/08/2019, p. 79/121
78/99 of rapid dissolution with an absorption enhancer each containing a modulator of neurotransmitter activity and a purified psilocybin derivative.
[00330] In one embodiment, the methods described in this document comprise transmucosal administration of a composition to cross a blood-brain barrier.
[00331] As used herein, the term transmucosal administration refers to the delivery of a compound, inserting through, or through, a mucous membrane, for example, an oral administration of a composition. In one embodiment, transmucosal administration refers to the administration of a drug through the cavity between the cheek and the gums, for example, a liquid composition, a rapidly dissolving tablet, a plaster, etc. In one embodiment, transmucosal administration refers to the administration of a drug under the tongue, for example, a liquid composition, a fast-dissolving tablet, a plaster, etc. The embodiment, transmucosal administration, refers to the administration of a drug through the upper gastrointestinal system, for example, a sublingual formulation or a liquid preparation with a permeation enhancer, a tablet, a food product, etc.
[00332] In one embodiment, the methods described in this document comprise the transdermal administration of a composition.
[00333] As used here, the term transdermal administration refers to providing a compound by entering the bloodstream or the body through the dermis or skin of an organism. In one embodiment, transdermal administration comprises applying a composition to the skin of an organism, for example, applying a topical composition, applying a liquid composition, etc. In one embodiment, transdermal administration of a composition comprises applying a patch soaked with the composition to the skin of an organism.
Petition 870190082150, of 22/08/2019, p. 80/121
79/99 [00334] As used here, the term neurotransmitter activity modulator refers to a compound or composition that reacts or influences activity at a neurotransmitter receptor, for example, a serotonergic drug, an adrenergic receptor, a dopamine, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycinergic receptor, etc. In one embodiment, a neurotransmitter activity modulator binds to a neurotransmitter receptor. In one embodiment, a neurotransmitter activity modulator indirectly affects a neurotransmitter receptor, for example, through interactions that affect the reactivity of other molecules in a neurotransmitter receptor. In one embodiment, a neurotransmitter activity modulator is an agonist. In one embodiment, a neurotransmitter activity modulator is an antagonist. In one embodiment, a neurotransmitter activity modulator acts (directly or indirectly) on more than one type of neurotransmitter receptor.
[00335] In one embodiment, a neurotransmitter activity modulator is chosen from aripiprazole, bupropion, citalopram, clomipramine, dextroamphetamine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, quetiaxine, serotinine, quetiapine, rheethaxine, quetiaxine, quetiapine, rheethaxine, quetiapine, rheethaxine.
[00336] As used here, the term "first dosage formulation" refers to a compound or compounds selected for the purpose of causing a reaction, effect and / or result, for example, to cause activity in a neurotransmitter receptor , to react with other compounds, to increase the effects of other active ingredients, to inhibit the biosynthesis of a compound, etc., within an organism. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative. In a way
Petition 870190082150, of 22/08/2019, p. 81/121
80/99 of embodiment, a first dosage formulation comprises a first purified cannabinoid. In one embodiment, a first dosage formulation comprises a first purified terpene. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative and a second purified psilocybin derivative. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative and a first purified cannabinoid. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative and a first purified terpene. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative, a first purified cannabinoid and a first purified terpene. In one embodiment, a first dosage formulation comprises a first purified psilocybin derivative and a modulator of neurotransmitter activity.
[00337] In one embodiment, a second dosage formulation comprises a first purified psilocybin derivative. In one embodiment, a second dosage formulation comprises a second purified psilocybin derivative. In one embodiment, a second dosage form comprises a first purified cannabinoid. In one embodiment, a second dosage formulation comprises a first purified terpene. In one embodiment, a second dosage formulation comprises a first purified psilocybin derivative and a first purified cannabinoid. In one embodiment, a second dosage formulation comprises a first purified psilocybin derivative and a first purified terpene. In one embodiment, a second dosage formulation comprises a first purified psilocybin derivative, a first purified cannabinoid and a first purified terpene. In one embodiment, a
Petition 870190082150, of 22/08/2019, p. 82/121
The second dosage formulation comprises a first purified psilocybin derivative and a modulator of neurotransmitter activity.
[00338] In one embodiment, the methods described in this document comprise administering a second dosage formulation. In one embodiment, the methods described in this document comprise administering a third dosage formulation. In one embodiment, the methods described in this document comprise administering a fourth dosage formulation. In one embodiment, the methods described in this document comprise administering more than four dosage formulations.
[00339] In one embodiment, the methods described in this document comprise administering one or more active ingredients, for example, psilocybin derivatives, cannabinoids, terpenes, modulators of neurotransmitter activity, etc., in a single dosage, for example, a single pill, single composition, single formulation, etc.
[00340] In one embodiment, the methods described in this document comprise administering one or more active ingredients, for example, psilocybin derivatives, cannabinoids, terpenes, modulators of neurotransmitter activity, etc., in more than two doses, for example , two or more tablets, or two more compositions, two or more formulations, etc.
[00341] This document describes a method for the treatment of a psychological problem, which comprises:
identifying a person in need of treatment, and administering a first purified psilocybin derivative to the person in need of treatment, where the first purified psilocybin derivative modulates activity in a neurotransmitter receptor.
[00342] As used here, the term identify a person in need of treatment refers to analyzing, diagnosing and / or determining whether a
Petition 870190082150, of 22/08/2019, p. 83/121
82/99 a person needs a composition that modulates activity in a neurotransmitter receptor. In one embodiment, identifying a person in need of treatment comprises diagnosing a person with a medical condition, for example, a neurological disorder, a chemical imbalance, a hereditary condition, etc. In one embodiment, identifying a person in need of treatment involves performing a psychiatric assessment. In one embodiment, identifying a person in need of treatment involves performing a blood test. In one embodiment, identifying a person in need of treatment involves determining whether a person has a compulsive disorder. In one embodiment, identifying a person in need of treatment understands self-identification as having a compulsive disorder.
[00343] As used here, the term psychological disorder refers to a condition in which a person has a pattern of behavioral and / or psychological symptoms that impact multiple areas of life and create distress for the person suffering from these symptoms. In one embodiment, a psychological disorder is caused by a genetic disorder. In one embodiment, a psychological disorder is caused by a biological condition, for example, excessive production of hormones, lack of activity in a neurotransmitter receptor, lack of production of neurotransmitters, etc. In one embodiment, the neurotransmitter receptor is a serotonin receptor.
[00344] In one embodiment, the psychological problem is an anxiety disorder. In one embodiment, the psychological problem is a depressive disorder. In one embodiment, the psychological problem is a compulsive disorder.
[00345] As used here, the term anxiety disorder refers to a state of apprehension, uncertainty, and / or fear resulting from the anticipation of an event and / or situation. An anxiety disorder can alter physical functions and
Petition 870190082150, of 22/08/2019, p. 84/121
83/99 psychological problems of a person. These disorders can cause a small obstacle to a debilitating incapacity for a person's daily life. An anxiety disorder can cause a physiological symptom, for example, muscle tension, heart palpitations, sweating, dizziness, shortness of breath, etc. An anxiety disorder can also cause a psychological symptom, for example, fear of dying, fear of embarrassment or humiliation, fear of an event occurring, etc.
[00346] In one embodiment, an anxiety disorder comprises acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, phobia, post-traumatic stress disorder, disorder separation anxiety, social anxiety disorder, substance-induced anxiety disorder, or selective mutism.
[00347] As used here, the term acute stress disorder refers to a condition developed after exposure to one or more traumatic events. Examples of traumatic events include, but are not limited to, exposure to war, rape or sexual violence, a physical attack, an assault, child physical or sexual violence, kidnapping or being taken hostage, terrorist attacks, torture, natural disasters and / or serious accidents. In one embodiment, the acute stress disorder occurs within a day after experiencing a traumatic event. In one embodiment, the acute stress disorder occurs within three days after experiencing a traumatic event. In some cases, the acute stress disorder occurs within a week after experiencing a traumatic event. In some cases, the acute stress disorder occurs within a month after experiencing a traumatic event.
[00348] As used here, the term "anxiety due to another medical condition" refers to a condition in which anxiety symptoms are developed due to a physiological and psychological consequence of an illness,
Petition 870190082150, of 22/08/2019, p. 85/121
84/99 unrelated injury and / or illness, for example, an endocrine disorder, a cardiovascular disorder, respiratory disease, metabolic disorder, neurological disease, etc.
[00349] As used here, the term generalized anxiety disorder refers to a condition of anxiety and persistent and excessive concern about various subjects, for example, work, school, social environments, etc., which an individual finds difficult to control . In addition, the individual experiences physical symptoms, including restlessness, alertness and / or nervousness; become easily fatigued, difficulty concentrating or memory failures, irritability, muscle tension and sleep disorders.
[00350] As used here, the term panic disorder refers to a condition in which an individual experiences recurring and unexpected panic attacks. The individual is persistently concerned about having more panic attacks and changes his behavior in maladaptive ways because of these panic attacks, for example, he avoids exercise, unknown places, new people, etc.
[00351] As used here, the term "panic attack" refers to an abrupt wave of intense fear or intense discomfort that reaches a peak within a short period of time, for example, seconds, minutes, hours, etc. In some cases, a panic attack comprises a physical and / or cognitive symptom. Panic attacks can be predictable, as in response to an object or situation typically feared. In some cases, a panic attack occurs for no apparent reason.
[00352] As used here, the term "phobia" refers to a condition of being afraid, anxious or being evasive to an object and / or limited situation. In some cases, a phobia comprises fear, anxiety or avoidance induced by a situation that is persistent and disproportionate to the actual risk presented. Examples
Petition 870190082150, of 22/08/2019, p. 86/121
85/99 phobias include, but are not limited to, fear or anxiety due to an animal, a natural environment, an injection injury, etc.
[00353] As used here, the term posttraumatic stress disorder refers to a condition developed after experiencing and / or witnessing a traumatic event or knowing that a traumatic event happened to a loved one. In some cases, a person experiences symptoms of post-traumatic stress disorder within a week after experiencing the traumatic event. In some cases, a person has symptoms of posttraumatic stress disorder within a month after experiencing the traumatic event. In some cases, a person experiences symptoms of post-traumatic stress disorder within a year after experiencing the traumatic event. In some cases, a person has symptoms of post-traumatic stress disorder after a year or more after experiencing the traumatic event. In some cases, posttraumatic stress disorder comprises a person who relives the trauma event through intrusive distressing memories of the event, flashbacks and / or nightmares. In some cases, a symptom of post-traumatic stress disorder comprises emotional numbness and avoidance of places, people and activities that resemble trauma. In some cases, a symptom of post-traumatic stress disorder includes increased arousal, such as difficulty sleeping and concentration, feeling anxious and being easily irritated and angry.
[00354] As used here, the term separation anxiety disorder refers to a condition in which an individual experiences fear and / or anxiety about separation from an attachment figure to a degree that is inappropriate in terms of development. In some cases, a separation anxiety disorder comprises a fear or anxiety about the damage that can occur to an attachment figure. In some cases, a separation anxiety disorder comprises the fear of an event that leads to the loss or separation of a person.
Petition 870190082150, of 22/08/2019, p. 87/121
86/99 attachment figure and the reluctance to move away from attachment figures. In some cases, a separation anxiety disorder comprises a nightmare and / or psychic symptom of distress.
[00355] As used here, the term social anxiety disorder refers to a condition in which an individual experiences fear, anxiety or avoids social interactions and situations that involve the possibility of being analyzed. These interactions and social situations include encounters with strangers, situations in which the individual can be observed eating or drinking, situations in which the individual appears before others, etc. In some cases, a social anxiety disorder is caused by the fear of being negatively evaluated by others, of being embarrassed, humiliated, rejected and / or offending others.
[00356] As used here, the term substance-induced anxiety disorder refers to a condition in which the anxiety is caused by intoxication and / or withdrawal / withdrawal from the substance or medical treatment. In some cases, withdrawal / withdrawal from a substance increases anxiety.
[00357] As used here, the term “selective mutism” refers to a condition characterized by the individual's consistent failure to speak in social situations where there is an expectation to speak, for example, school, a lecture, a meeting, etc. . even if the individual speaks in other situations. Failure to speak has significant consequences on academic performance, occupational environments and / or interferes in any way with normal media.
[00358] In some cases, an anxiety disorder comprises a medical diagnosis based on the criteria and classification of the Diagnostic and Statistical Manual of Medical Disorders, 5th Ed. In some cases, an anxiety disorder comprises a medical diagnosis based on a medical evaluation independent. In some cases, an anxiety disorder comprises a medical diagnosis based on a self-assessment.
Petition 870190082150, of 22/08/2019, p. 88/121
87/99 [00359] In one embodiment, the methods and compositions described in this document comprise administering an anxiolytic drug.
[00360] As used herein, the term anxiolytic drug refers to a compound or composition that reacts or influences activity on a neurotransmitter receptor, for example, a serotonergic drug, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycinergic receptor, etc. In one embodiment, an anxiolytic drug binds to a neurotransmitter receptor. In one embodiment, an anxiolytic drug indirectly affects a neurotransmitter receptor, for example, through interactions that affect the reactivity of other molecules in a neurotransmitter receptor. In one embodiment, an anxiolytic drug is an agonist. In one embodiment, an anxiolytic drug is an antagonist. In one embodiment, an anxiolytic drug acts (directly or indirectly) on more than one type of neurotransmitter receptor.
[00361] In one embodiment, an anxiolytic drug is chosen from alprazolam, an alpha-blocker, an antihistamine, a barbiturate, a beta-blocker, bromazepam, a carbamate, chlordiazepoxide, clonazepam, chlorazepate, diazepam, flurazepam, lorazepam, lorazepam an opioid, oxazepam, temazepam or triazolam.
[00362] As used here, the term depressive disorder refers to a condition of moodiness and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being that last for a period of time . In one embodiment, a depressive disorder alters a person's physical and psychological functions. In one embodiment, a depressive disorder causes a physiological symptom, for example, weight loss, aches or pains, headaches, cramps, digestive problems, etc. In one embodiment, a depressive disorder causes a psychological symptom, for
Petition 870190082150, of 22/08/2019, p. 89/121
88/99 example, persistent sadness; anxiety; feeling of hopelessness and irritability; feeling of guilt, worthlessness or helplessness; loss of interest or pleasure in hobbies and activities; difficulty concentrating, remembering or making decisions, etc.
[00363] In one embodiment, a depressive disorder is chosen from atypical depression, bipolar disorder, catatonic depression, depressive disorder due to a medical condition, major depressive disorder, postpartum depression, premenstrual dysphoric disorder or affective disorder seasonal.
[00364] As used here, the term atypical depression refers to a condition in which an individual shows signs of mood reactivity (ie reactive mood in response to real or potential positive events), significant weight gain, increased appetite, hypersomnia, feeling of heaviness in the arms or legs and / or a pattern of sensitivity to long-standing interpersonal rejection that results in significant social or occupational impairment. Examples of symptoms of atypical depression include, but are not limited to, daily sadness or depressed mood; loss of joy in things that were once pleasurable; major changes in weight (gain or loss) or appetite; insomnia or excessive sleep almost every day; a state of physical restlessness or degradation that is noticeable to others; daily fatigue or loss of energy; feelings of hopelessness, worthlessness or excessive guilt almost every day; problems with concentration or decision-making almost every day; recurring thoughts of death or suicide, suicide plan or attempted suicide.
[00365] As used here, the term bipolar disorder refers to a condition that causes an individual to experience unusual changes in mood, energy, activity levels and the ability to perform everyday tasks. Individuals with bipolar disorder experience unusual periods of intense emotion, changes in sleep patterns and unusual levels of activity and behavior. These distinct periods are called "mood episodes". The episodes of
Petition 870190082150, of 22/08/2019, p. 90/121
89/99 moods are drastically different from the typical moods and behaviors of the person. Examples of manic / euphoric symptoms, excessive behavior, include, but are not limited to, abnormally optimistic, bouncing, or wired behavior; increased activity, energy or agitation; exaggerated sense of well-being and self-confidence; decreased need for sleep; unusual loquacity; uncontrolled thoughts; distraction; and wrong decision making - for example, continuing to buy, taking sexual risks or making foolish investments. Examples of symptoms of depressive episodes, moodiness, include, but are not limited to, depressive mood, such as feeling sad, empty, hopeless or crying; marked loss of interest or not feeling pleasure in all - or almost all - activities; significant weight loss, weight gain or decreased or increased appetite; insomnia or sleeping too much; restlessness or deceleration behavior; fatigue or loss of energy; feelings of worthlessness or excessive or improper guilt; decreased ability to think or focus, or indecision; and think, plan or attempt suicide.
[00366] As used here, the term catatonic depression refers to a condition that causes an individual to remain speechless and immobile for a prolonged period. Examples of symptoms of catatonic depression include, but are not limited to, the feeling of sadness, which can occur daily, loss of interest in most activities, sudden weight gain or loss, change in appetite, difficulty sleeping, difficulty getting out of bed , feeling of restlessness, irritability, feeling of worthlessness, feeling of guilt, fatigue, difficulty concentrating, difficulty thinking, difficulty making decisions, suicidal thoughts or death and / or attempted suicide.
[00367] As used here, the term depressive disorder due to a medical condition refers to a condition in which an individual experiences depressive symptoms caused by another disease. Examples of medical conditions
Petition 870190082150, of 22/08/2019, p. 91/121
90/99 known to cause a depressive disorder include, but are not limited to HIV / AIDS, diabetes, arthritis, strokes, brain disorders such as Parkinson's disease, Huntington's disease, multiple sclerosis and Alzheimer's disease, metabolic conditions ( for example, vitamin B12 deficiency), autoimmune conditions (for example, lupus and rheumatoid arthritis), viral or other infections (hepatitis, mononucleosis, herpes), back pain and certain types of cancer (for example, pancreatic).
[00368] As used here, the term major depressive disorder refers to a condition characterized by a period of bad mood that is present in most situations. Major depressive disorder is often accompanied by low self-esteem, loss of interest in normally pleasant activities, low energy and pain without an apparent cause. In some cases, major depressive disorder is characterized by two weeks. In some cases, an individual experiences periods of depression separated by years. In some cases, an individual has symptoms of depression that are almost always present. Major depressive disorder can negatively affect a person's personal, professional or school life, as well as sleep, eating habits and health in general. 2 - 7% of adults with major depressive disorder commit suicide and up to 60% of people who commit suicide have major depressive disorder or other related mood disorder. Dysthymia is a subtype of major depressive disorder that consists of the same physical and cognitive problems as major depressive disorder, with less severe but more lasting symptoms. Examples of symptoms of a major depressive disorder include, but are not limited to feelings of sadness, crying, emptiness or hopelessness; outbursts of anger, irritability or frustration, even on small matters; loss of interest or pleasure in most or all normal activities; sleep disorders, including insomnia or sleeping too much; tiredness and lack of energy; reduced appetite, weight loss or gain; anxiety,
Petition 870190082150, of 22/08/2019, p. 92/121
91/99 agitation or restlessness; slowed thoughts, speech or bodily movements; feelings of worthlessness or guilt, fixing on past failures or self-blame; difficulty thinking, concentrating, making decisions and remembering things; frequent thoughts of death, suicidal thoughts, suicide attempts or suicide; and unexplained physical problems, such as back pain or headaches.
[00369] As used here, the term postpartum depression refers to a condition resulting from childbirth and hormonal changes, psychological adjustment to parenthood and / or fatigue. Postpartum depression is often associated with women, but men can also suffer from postpartum depression. Examples of symptoms of postpartum depression include, but are not limited to feelings of sadness, hopelessness, emptiness or overload; cry more often than usual or for no apparent reason; worrying or feeling excessively anxious; feeling moody, irritable or restless; sleeping too much or not being able to sleep even when the baby is sleeping; having difficulty concentrating, remembering details and making decisions; feel anger or fury; losing interest in activities that are generally enjoyable; suffering from physical pain, including frequent headaches, stomach problems and muscle pain; eating too little or too much; avoid or get away from friends and family; having difficulty connecting or forming an emotional bond with the baby; persistently doubting your ability to care for the baby; and think about getting hurt or hurting the baby.
[00370] As used here, the term premenstrual dysphoric disorder refers to a condition in which an individual expresses symptoms of mood lability, irritability, dysphoria and anxiety that occur repeatedly during the premenstrual phase of the cycle and refer to the onset of menstruation or shortly thereafter. Examples of symptoms of premenstrual dysphoric disorder include, but are not limited to, instability (eg mood swings), irritability or anger,
Petition 870190082150, of 22/08/2019, p. 93/121
92/99 depressed mood, anxiety and tension, decreased interest in usual activities, difficulty concentrating, lethargy and lack of energy, changes in appetite (eg excessive or specific binge eating), hypersomnia or insomnia, feeling overwhelmed or out control symptoms, physical symptoms (for example, breast tenderness or swelling, pain in the joints or muscles, feeling of swelling and weight gain), derogatory thoughts, feelings of being excited or depressed, decreased interest in usual activities (for example, work, school, friends, hobbies), subjective difficulty in concentrating and getting tired easily.
[00371] As used here, the term seasonal affective disorder refers to a condition in which an individual experiences mood changes based on the time of year. In some cases, an individual experiences a bad mood, low energy or other depressive symptoms during autumn and / or winter. In some cases, an individual experiences a bad mood, low energy or other depressive symptoms during the spring and / or summer. Examples of symptoms of seasonal affective disorder include, but are not limited to feeling depressed most or most of the day; losing interest in previously pleasant activities; have little energy; having problems with sleep; experiencing changes in appetite or weight; feel slow or restless; having difficulty concentrating; feeling hopeless, worthless or guilty; and having frequent thoughts of death or suicide.
[00372] In one embodiment, a depressive disorder comprises a medical diagnosis based on the criteria and classification of the Diagnostic and Statistical Manual of Medical Disorders, 5- Ed. In one embodiment, a depressive disorder comprises a medical diagnosis based on independent medical evaluation.
[00373] In one embodiment, the methods and compositions described
Petition 870190082150, of 22/08/2019, p. 94/121
93/99 in this document comprises administering an antidepressant.
[00374] As used here, the term antidepressant refers to a compound or compounds that react or influence activity at a neurotransmitter receptor, for example, a serotonergic drug, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycinergic receptor, etc. In one embodiment, an antidepressant binds to a neurotransmitter receptor. In one embodiment, an antidepressant indirectly affects a neurotransmitter receptor, for example, through interactions that affect the reactivity of other molecules in a neurotransmitter receptor. In one embodiment, an antidepressant is an agonist. In one embodiment, an antidepressant is an antagonist. In one embodiment, an antidepressant acts (directly or indirectly) on more than one type of neurotransmitter receptor.
[00375] In one embodiment, an antidepressant is chosen from buproprion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline and venlafaxine.
[00376] This document describes a method for the treatment of headaches and / or migraines, which comprises identifying a person in need of treatment and administering a composition described here to the person in need of treatment.
[00377] This document describes a method for the treatment of nicotine addiction, which comprises identifying a person in need of treatment and administering a composition described here to the person in need of treatment.
[00378] This document describes a method for the treatment of drug addiction, which comprises identifying a person who needs
Petition 870190082150, of 22/08/2019, p. 95/121
94/99 treatment and administer a composition described here to the person in need of treatment.
[00379] This document describes a method for the treatment of alcohol dependence, which comprises identifying a person in need of treatment and administering a composition described here to the person in need of treatment.
[00380] The compositions described in this document are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol addiction. The compositions described in this document are also useful within the context of meditative, spiritual and religious practices within a variety of contexts.
[00381] As used here, the term compulsive disorder refers to a condition in which an individual has an obsession that causes a feeling of anxiety, fear, apprehension, etc., and has a compulsion to perform tasks to relieve the feeling of anxiety. An obsession is a thought that is repeated and persists despite an individual's efforts to ignore or confront them. In some cases, an obsession is relatively vague, involving a general feeling of disorder or tension, accompanied by a belief that life cannot proceed normally as long as the imbalance remains. In other cases, an obsession is more intense and can be a concern with the thought or image of someone close to them or with intrusions related to the correction of the relationship. Other obsessions concern the possibility that someone or something other than yourself - like God, the Devil or illness - could harm the person, people or things that they care about. In some cases, individuals perform compulsive rituals because, inexplicably, they feel the need. In some cases, individuals perform compulsive rituals to mitigate the anxiety that
Petition 870190082150, of 22/08/2019, p. 96/121
95/99 arises from a particular obsession. The person feels that these actions will in some way prevent a feared event from occurring or take the event out of his thoughts.
[00382] In one embodiment, a compulsive disorder is chosen from dependence, excoriation disorder, accumulation disorder, obsessive compulsive disorder and trichotillomania.
[00383] As used here, the term dependence refers to a physical and / or psychological dependence on a substance, activity and / or any other habit. In one embodiment, an addiction is caused by an individual's altered brain chemistry in response to a stimulus, for example, a substance that releases large amounts of serotonin, an activity that releases large amounts of adrenaline, etc. In one embodiment, an addiction is a dependence on a substance, for example, a drug, an alcohol, nicotine, a food, etc. In one embodiment, an addiction is a dependency on an activity, for example, gambling, eating, shopping, etc.
[00384] As used here, the term body dysmorphic disorder refers to a condition characterized by the obsessive idea that some aspect of an individual's appearance is seriously flawed and deserves exceptional measures to hide or repair it. Examples of symptoms of body dysmorphic disorder include, but are not limited to, being extremely concerned about a visible flaw in appearance that, to others, cannot be seen or appears small; a belief that a defect in appearance makes an individual ugly or deformed; a belief that others pay special attention to an individual's appearance in a negative way or make fun of the individual; engaging in behaviors that aim to repair or hide the perceived flaw, which are difficult to resist or control, such as frequently checking the mirror, cleaning or scarring the skin; trying to hide perceived flaws with beauty treatments, makeup or clothing; constantly compare someone's appearance with others; always seek reaffirmation of
Petition 870190082150, of 22/08/2019, p. 97/121
96/99 someone about their appearance; have perfectionist tendencies; seek frequent cosmetic procedures with little satisfaction; avoid social situations; and being so concerned with appearance that it leads to great distress or problems in a person's social life, work, school or other occupational areas.
[00385] As used here, the term excoriation disorder refers to a condition in which there is a frequent desire to excoriate the skin itself. In some cases, an excoriation disorder causes a person to frequently excoriate the skin to the extent that damage is caused.
[00386] As used here, the term accumulation disorder refers to a condition of persistent difficulty in discarding or separating from belongings, regardless of their value. Examples of symptoms of an accumulation disorder include, but are not limited to, an inability to throw away belongings; marked anxiety when trying to discard items; great difficulty in categorizing or organizing belongings; indecision on what to keep or where to put things; distress, like feeling overwhelmed or embarrassed by belongings; suspected that other people are touching the items; obsessive thoughts and actions; fear of running out of an item or needing it in the future; check garbage for accidentally discarded objects; and functional deficiencies, for example, loss of living space, social isolation, family or marital discord, financial difficulties, health risks, etc.
[00387] As used here, the term obsessive compulsive disorder refers to a condition in which an individual has uncontrollable and recurring thoughts and behaviors in which the desire to repeat frequently is felt. In some cases, an obsessive-compulsive disorder manifests itself when an individual needs to clean something in order to reduce the fear that germs, dirt or chemicals will contaminate the individual, where the individual spends many hours washing or cleaning the environment. In some cases, an obsessive compulsive disorder
Petition 870190082150, of 22/08/2019, p. 98/121
97/99 manifests when an individual needs to dispel anxiety. An individual can pronounce a name, phrase or repeat behavior several times. The individual knows that these repetitions will not actually prevent the damage, but the fear of the damage will appear if the repetitions are not performed. In some cases, an obsessive compulsive disorder manifests itself when an individual needs to reduce the fear of hurting themselves or others, forgetting, for example, to lock the door or turn off appliances, to develop verification rituals, etc. In some cases, an obsessive compulsive disorder manifests itself when an individual needs to order and organize his environment in order to reduce discomfort, for example, placing objects in a certain order, arranging household items in a particular or symmetrical way, etc. In some cases, an obsessive-compulsive disorder manifests when an individual needs to respond to intrusive obsessive thoughts, for example, praying or saying phrases to reduce anxiety or prevent a feared future event. In some cases, obsessive compulsive disorder is caused by another medical condition. In some cases, obsessive compulsive disorder is caused by a substance.
[00388] As used here, the term trichotillomania refers to a condition of self-induced and recurrent hair loss such as, for example, pulling out one's own hair. In some cases, trichotillomania covers an individual who pulls their hair from a single location. In some cases, trichotillomania covers an individual who pulls their hair out from various places. Examples of symptoms of trichotillomania include, but are not limited to, recurring hair pulling, resulting in noticeable hair loss; an increased feeling of tension just before pulling your hair out or resisting behavior; pleasure, gratification or relief when pulling your hair out; the disorder is not explained by another mental disorder and is not due to a general medical condition (ie, dermatological condition); repeated attempts have been made to slow or stop hair pulling;
Petition 870190082150, of 22/08/2019, p. 99/121
98/99 disturbances caused significant suffering or impairment in social, occupational or other important operational areas; anguish, including feelings of loss of control, embarrassment, shame; and restraint when avoiding work, school or other public situations.
[00389] In one embodiment, a compulsive disorder comprises a medical diagnosis based on the criteria and classification of the Diagnostic and Statistical Manual of Medical Disorders, 5- Ed. In one embodiment, a compulsive disorder comprises a medical diagnosis based on independent medical evaluation.
[00390] Formulations comprising a composition described herein and at least one compound that does not act on serotonin receptors are described in this document.
[00391] Although the disclosed invention has been described with reference to several examples of embodiments, it should be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Those skilled in the art will recognize that various modifications can be made to the examples of embodiments, without departing from the scope of the invention.
[00392] When a reference to a particular compound is made, it should be understood that this disclosure also includes salts and derivatives of that compound, as well as degradation products, such as the oxidized versions of the molecules explicitly disclosed.
[00393] Furthermore, it should be understood that various properties and / or characteristics of the different embodiments can be combined with each other. Therefore, it should be understood that numerous modifications can be made to the illustrative embodiments and that other arrangements can be designed without departing from the scope of the invention.
Petition 870190082150, of 22/08/2019, p. 100/121
99/99 [00394] In addition, other embodiments of the invention will be evident to those skilled in the art considering the specification and practice of the invention disclosed in this document. It is intended that the specification and the examples are considered only as examples, the scope and spirit being indicated by the claims.
[00395] Finally, it is noted that, as used in this specification and in the appended claims, the singular forms one, one and the / include the plural references unless expressly and unambiguously limited to an indicative, and vice-versa versa. As used here, the term "include" or "comprising" and its grammatical variants are not intentionally limiting, so the recitation of an item or items should not exclude other similar items that can be replaced or added to the item (s) ( s) recited.

权利要求:
Claims (128)
[1]
1. Composition CHARACTERIZED for understanding:
a first purified psilocybin derivative; wherein the first purified psilocybin derivative is chosen from [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-methylaminoethyl) - 1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3- (2-trimethylaminoethyl ) -1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, N-trimethyltryptamine; and a second purified psilocybin derivative; wherein the second purified psilocybin derivative is chosen from [3- (2-dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N, N-dimethyltryptamine, [3- (2-methylaminoethyl) - 1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3- (aminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3- (2-trimethylaminoethyl )] - 1 H-indol-4-yl] dihydrogen phosphate and 4-hydroxy-N, N, N-trimethyltryptamine.
[2]
Composition according to claim 1, characterized in that it comprises a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[3]
Composition according to claim 1, characterized in that it comprises a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[4]
Composition according to claim 1, characterized in that it comprises a molar ratio of about 1000: 1 to about 1: 1000 between the first purified psilocybin derivative and the second purified psilocybin derivative.
[5]
Composition according to claim 1, characterized in that it comprises a molar ratio of about 10,000: 1 to about 1: 10,000 between the first purified psilocybin derivative and the second purified psilocybin derivative.
Petition 870190082150, of 22/08/2019, p. 102/121
2/17
[6]
6. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is [3- (2-dimethylaminoethyl) -1 Hindol-4-yl] dihydrogen phosphate.
[7]
7. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is 4-hydroxy-N, Ndimethyltryptamine.
[8]
8. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is [3- (2-methylaminoethyl) -1 Hindol-4-yl] dihydrogen phosphate.
[9]
9. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is 4-hydroxy-Nmethyltryptamine.
[10]
10. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is [3- (aminoethyl) -1 H-indol-4yl] dihydrogen phosphate.
[11]
11. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is 4-hydroxytryptamine.
[12]
12. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is [3- (2-trimethylaminoethyl) 1 H-indol-4-yl] dihydrogen phosphate.
[13]
13. Composition according to claim 1, CHARACTERIZED by the fact that the first purified psilocybin derivative is 4-hydroxy-N, N, Ntrimethyltryptamine.
[14]
14. Composition according to claim 1, characterized by comprising a first purified cannabinoid.
[15]
15. Composition, according to claim 14, CHARACTERIZED by the fact that the first purified cannabinoid is chosen from THC, THCA, THCV,
Petition 870190082150, of 22/08/2019, p. 103/121
3/17
THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV or CBGVA.
[16]
16. Composition according to claim 15, characterized in that it comprises a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified cannabinoid.
[17]
Composition according to claim 16, characterized in that it comprises a molar ratio of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified cannabinoid.
[18]
18. The composition of claim 17, characterized in that it comprises a molar ratio of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified cannabinoid.
[19]
19. Composition according to claim 18, characterized in that it comprises a molar ratio of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified cannabinoid.
[20]
20. Composition according to claim 19, characterized in that it comprises a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified cannabinoid.
[21]
21. Composition according to claim 20, characterized in that it comprises a molar ratio of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified cannabinoid.
[22]
22. Composition according to claim 21, CHARACTERIZED by the fact that the first purified psilocybin derivative and the first purified cannabinoid are present as a homogeneous mixture.
[23]
23. Composition according to claim 1, characterized in that it comprises a first purified terpene.
[24]
24. Composition according to claim 23, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alpha
Petition 870190082150, of 22/08/2019, p. 104/121
4/17 bisabolol, borneol, camphor, camphor, carene, beta-karyophylene, cedrene, cimene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalol, menthol, beta-myrene, nerolid, nerolid , ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[25]
25. Composition according to claim 24, characterized in that it comprises a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified terpene.
[26]
26. Composition according to claim 25, characterized in that it comprises a molar ratio of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified terpene.
[27]
27. Composition according to claim 26, characterized in that it comprises a molar ratio of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified terpene.
[28]
28. The composition of claim 27, wherein it comprises a molar ratio of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified terpene.
[29]
29. The composition of claim 28, wherein it comprises a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified terpene.
[30]
Composition according to claim 29, characterized in that it comprises a molar ratio of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified terpene.
[31]
31. Composition according to claim 23, CHARACTERIZED by the fact that the first purified psilocybin derivative and the first purified terpene are present as a homogeneous mixture.
[32]
32. Composition according to claim 1, CHARACTERIZED in that it comprises a first purified cannabinoid and a first purified terpene.
Petition 870190082150, of 22/08/2019, p. 105/121
5/17
[33]
33. Composition according to claim 32, CHARACTERIZED by the fact that the first purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA , CBGV or CBGVA.
[34]
34. Composition, according to claim 33, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alfabisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cimene, elemene, eucaliptol, eudesmol , farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, beta-myrcene, nerolidol, ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[35]
35. Composition according to claim 34, characterized in that it comprises a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the first purified cannabinoid, and a molar ratio between 100: 1 at about 1: 100 between the first purified psilocybin derivative and the first purified terpene.
[36]
36. Composition according to claim 35, characterized in that it comprises a molar ratio of about 75: 1 to about 1:75 between the first purified psilocybin derivative and the first purified cannabinoid, and a molar ratio of about 75 : 1 at about 1:75 between the first purified psilocybin derivative and the first purified terpene.
[37]
37. Composition according to claim 36, characterized in that it comprises a molar ratio of about 50: 1 to about 1:50 between the first purified psilocybin derivative and the first purified cannabinoid, and a molar ratio of about 50 : 1 at about 1:50 between the first purified psilocybin derivative and the first purified terpene.
[38]
38. Composition according to claim 37, characterized in that it comprises a molar ratio of about 25: 1 to about 1:25 between the first
Petition 870190082150, of 22/08/2019, p. 106/121
6/17 purified psilocybin derivative and the first purified cannabinoid, and a molar ratio of about 25: 1 to about 1:25 between the first purified psilocybin derivative and the first purified terpene.
[39]
39. Composition according to claim 38, characterized in that it comprises a molar ratio of about 10: 1 to about 1:10 between the first purified psilocybin derivative and the first purified cannabinoid, and a molar ratio of about 10 : 1 at about 1:10 between the first purified psilocybin derivative and the first purified terpene.
[40]
40. Composition according to Claim 39, characterized in that it comprises a molar ratio of about 5: 1 to about 1: 5 between the first purified psilocybin derivative and the first purified cannabinoid, and a molar ratio of about 5 : 1 to about 1: 5 between the first purified psilocybin derivative and the first purified terpene.
[41]
41. Composition according to claim 32, CHARACTERIZED by the fact that the first purified psilocybin derivative, the first purified cannabinoid and the first purified terpene are present as a homogeneous mixture.
[42]
42. The composition of claim 14, characterized by comprising a second purified cannabinoid.
[43]
43. Composition according to claim 42, CHARACTERIZED by the fact that the first purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA , CBGV or CBGVA.
[44]
44. Composition according to claim 43, CHARACTERIZED by the fact that the second purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA , CBGV or CBGVA.
Petition 870190082150, of 22/08/2019, p. 107/121
7/17
[45]
45. Composition according to claim 44, characterized in that it comprises a molar ratio of about 100: 1 to about 1: 100 between the first purified psilocybin derivative and the sum of the first purified cannabinoid and the second purified cannabinoid.
[46]
46. Composition according to claim 45, CHARACTERIZED by the fact that the molar ratio is between about 75: 1 and about 1:75.
[47]
47. Composition according to claim 46, CHARACTERIZED by the fact that the molar ratio is between about 50: 1 and about 1:50.
[48]
48. Composition, according to the CHARACTERIZED claim by the fact that the molar ratio is between about 25: 1 and about 1:25.
[49]
49. Composition according to claim 48, CHARACTERIZED by the fact that the molar ratio is between about 10: 1 and about 1:10.
[50]
50. Composition according to claim 49, CHARACTERIZED by the fact that the molar ratio is between about 5: 1 and about 1: 5.
[51]
51. Composition according to claim 42, CHARACTERIZED by the fact that the first purified psilocybin derivative, the first purified cannabinoid and the second purified cannabinoid are present as a homogeneous mixture.
[52]
52. Composition FEATURED for comprising a first purified psilocybin derivative and a stabilizer.
[53]
53. Composition according to claim 52, CHARACTERIZED by the fact that the first purified psilocybin derivative is chosen from [3- (2dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N , N-dimethyltryptamine, 3 (2-methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3 (aminoethyl) -1 H-indol-4-yl] di- hydrogen phosphate, 4-hydroxytryptamine, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate or 4-hydroxy-N, N, Ntrimethyltryptamine.
Petition 870190082150, of 22/08/2019, p. 108/121
8/17
[54]
54. Composition according to claim 52, CHARACTERIZED by the fact that the stabilizer is an antioxidant.
[55]
55. Composition according to claim 54, CHARACTERIZED by the fact that the antioxidant contains a compound chosen from ascorbic acid, lycopene, tocopherol, melatonin, retinol, astaxanthin, lutein, apigenin, carnosine, selenium, zinc or cucurmine.
[56]
56. Composition according to claim 52, CHARACTERIZED by the fact that the stabilizer is a pH buffer.
[57]
57. Composition according to claim 56, CHARACTERIZED by the fact that the pH buffer comprises a compound chosen from citric acid, acetic acid, monosodium phosphate, N-cyclohexyl-2-aminoethanesulfonic acid, borate, hydrochloric acid, sodium hydroxide or salts thereof.
[58]
58. Composition according to claim 52, characterized in that it comprises a dephosphorylating agent.
[59]
59. Composition according to claim 52, characterized by comprising a first purified cannabinoid.
[60]
60. Composition according to claim 59, CHARACTERIZED by the fact that the first purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA , CBGV or CBGVA.
[61]
61. Composition according to claim 60, characterized in that it comprises a first purified terpene.
[62]
62. Composition according to claim 61, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alfabisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cimene, elemene, eucaliptol, eudesmol , farnesene, fenchol, geraniol, guaiacol, humulene,
Petition 870190082150, of 22/08/2019, p. 109/121
9/17 isoborneol, limonene, linalool, menthol, beta-mircene, nerolidol, ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[63]
63. Composition, according to claim 52, CHARACTERIZED by the fact that the composition comprises about 0-5% water by weight percentage.
[64]
64. Composition according to claim 52, CHARACTERIZED by the fact that the composition is soluble in water.
[65]
65. Composition according to claim 52, characterized in that it comprises an excipient.
[66]
66. Composition according to claim 65, CHARACTERIZED by the fact that the excipient comprises a compound chosen from Vitamin E TPGS, sodium lauryl sulfate, sucrose, alcohol, gelatin, polyvinylpyrrolidone, methionine, dimethylsulfoxide, tartrazine, polyethylene glycol, stearate magnesium, stearic acid, smoked silica, talc, magnesium carbonate or benzalkonium chloride.
[67]
67. Composition according to claim 66, CHARACTERIZED by the fact that the excipient is Vitamin E TPGS.
[68]
68. Composition according to claim 52, and CHARACTERIZED by the fact that the first purified psilocybin derivative is a dry powder.
[69]
69. Composition according to claim 52, characterized in that it comprises a solvent and an excipient.
[70]
70. Composition according to claim 69, CHARACTERIZED by the fact that the stabilizer is an antioxidant.
[71]
71. Composition according to claim 70, CHARACTERIZED by the fact that the antioxidant comprises a compound chosen from ascorbic acid, lycopene, tocopherol, melatonin, retinol, astaxanthin, lutein, apigenin, carnosine, selenium, zinc or cucurmine.
Petition 870190082150, of 22/08/2019, p. 110/121
10/17
[72]
72. Composition according to claim 69, CHARACTERIZED by the fact that the stabilizer is a pH buffer.
[73]
73. Composition according to claim 72, CHARACTERIZED by the fact that the pH buffer comprises a compound chosen from citric acid, acetic acid, monosodium phosphate, N-cyclohexyl-2-aminoethanesulfonic acid, borate, hydrochloric acid or hydroxide sodium.
[74]
74. Composition according to claim 69, characterized in that it comprises a first purified cannabinoid.
[75]
75. Composition according to claim 74, CHARACTERIZED by the fact that the first cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV or CBGVA.
[76]
76. Composition according to claim 69, characterized in that it comprises a first purified terpene.
[77]
77. Composition, according to claim 76, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alfabisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cimene, elemene, eucaliptol, eudesmol , farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, beta-mircene, nerolidol, ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[78]
78. Composition according to claim 69, CHARACTERIZED by the fact that the excipient comprises a compound chosen from Vitamin E TPGS, sodium lauryl sulfate, sucrose, alcohol, gelatin, polyvinylpyrrolidone, methionine, dimethylsulfoxide, tartrazine, polyethylene glycol, stearate magnesium, stearic acid, smoked silica, talc, magnesium carbonate or benzalkonium chloride.
[79]
79. Composition according to claim 78, CHARACTERIZED by the fact that the excipient is Vitamin E TPGS.
Petition 870190082150, of 22/08/2019, p. 111/121
11/17
[80]
80. Composition according to claim 69, CHARACTERIZED by the fact that the solvent is water.
[81]
81. Composition according to claim 69, characterized in that it comprises a dephosphorylating agent.
[82]
82. Method of modulating activity in a neurotransmitter receptor FEATURED for comprising administering a modulator of neurotransmitter activity and administering a first dosage formulation comprising a first purified psilocybin derivative to the person in need of treatment, in which the first dosage formulation modulates activity at a neurotransmitter receptor.
[83]
83. The method of claim 82, CHARACTERIZED by the fact that the first purified psilocybin derivative is chosen from [3- (2dimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N , N-dimethyltryptamine, [3 (2-methylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3 (aminoethyl) -1 H-indol-4-yl] di -hydrogenphosphate, 4-hydroxytryptamine, [3- (2-trimethylaminoethyl) -1 H-indol-4-yl] dihydrogen phosphate or 4-hydroxy-N, N, Ntrimethyltryptamine.
[84]
84. The method of claim 83, comprising dephosphorylating the first purified psilocybin derivative.
[85]
85. The method of claim 82, comprising administering a monoamine oxidase inhibitor.
[86]
86. Method according to claim 82, CHARACTERIZED by the fact that the neurotransmitter receptor is chosen from a serotonin receptor, a cannabinoid receptor, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycine receptor.
Petition 870190082150, of 22/08/2019, p. 112/121
12/17
[87]
87. Method according to claim 86, CHARACTERIZED by the fact that the neurotransmitter receptor is a serotonin receptor.
[88]
88. Method, according to claim 87, CHARACTERIZED by the fact that the neurotransmitter activity modulator is a serotonergic drug.
[89]
89. Method according to claim 88, CHARACTERIZED by the fact that the serotoninergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, clordiazepox, citalopram, clonazole, clonazole, chloride dextromethorphan, diazepam, duloxetine, escitalopram, fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4-methylenedioxymethamphetamine, milnacipran, mirtazapine, naratripine, oxetamine, paroxetine, paroxetine, paroxetine, paroxetine, paroxetine, serotonin, sertraline, temazepam, tramadol, triazolam, a tryptamine, venlafaxine or vortioxetine.
[90]
90. Method according to claim 86, CHARACTERIZED by the fact that the neurotransmitter receptor is an adrenergic receptor.
[91]
91. Method, according to claim 90, CHARACTERIZED by the fact that the neurotransmitter activity modulator is an adrenergic drug.
[92]
92. Method, according to claim 91, CHARACTERIZED by the fact that the adrenergic drug is chosen from adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepine, duloxetine, esmirtazpine, mianserine, mirabegron, mirabegron, mirtaine phentolamine, phenylephrine, piperoxane, reserpine, ritodrine, setiptyline, tesofensina, timolol, trazodone, trimipramine or xylazine.
[93]
93. The method of claim 93, characterized by the fact that the neurotransmitter receptor is a dopaminergic receptor.
[94]
94. Method according to claim 93, CHARACTERIZED by the fact that the neurotransmitter activity modulator is a dopaminergic drug.
Petition 870190082150, of 22/08/2019, p. 113/121
13/17
[95]
95. Method according to claim 94, CHARACTERIZED by the fact that the dopaminergic drug is chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, flufenazine, halphenidine, flufenazine loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, pyribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine or thioridazine.
[96]
96. Method according to claim 82, CHARACTERIZED by the fact that the administration of a first dosage formulation comprises a first purified cannabinoid.
[97]
97. Method according to claim 96, CHARACTERIZED by the fact that the first purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA , CBGV or CBGVA.
[98]
98. Method according to claim 96, CHARACTERIZED by the fact that the administration of a first dosage formulation comprises a first purified terpene.
[99]
99. Method according to claim 98, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alfabisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cimene, elemene, eucaliptol, eudesmol , farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, beta-mircene, nerolidol, ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[100]
100. The method of claim 82, characterized in that it comprises administering an excipient.
[101]
101. Method, according to claim 100, CHARACTERIZED by the fact that the excipient comprises a compound chosen from lauryl sulfate of
Petition 870190082150, of 22/08/2019, p. 114/121
14/17 sodium, sucrose, alcohol, gelatin, polyvinylpyrrolidone, methionine, Vitamin E TPGS, dimethylsulfoxide, tartrazine, polyethylene glycol, magnesium stearate, stearic acid, smoked silica, talc, magnesium carbonate or benzalkonium chloride.
[102]
102. Method for treating a psychological disorder CHARACTERIZED by understanding to identify a person in need of treatment, and administering a first purified psilocybin derivative to the person in need of treatment, in which the first purified psilocybin derivative modulates activity in a neurotransmitter receptor .
[103]
103. Method according to claim 102, CHARACTERIZED by the fact that the neurotransmitter receptor is chosen from a serotonin receptor, an adrenergic receptor, a dopamine receptor, a GABAergic receptor, a glutaminergic receptor, a histaminergic receptor, a cholinergic receptor, an opioid receptor or a glycinergic receptor.
[104]
104. The method of claim 102, comprising dephosphorylating the first purified psilocybin derivative.
[105]
105. The method of claim 102, comprising administering a monoamine oxidase inhibitor.
[106]
106. The method of claim 102, characterized in that it comprises administering a first purified cannabinoid.
[107]
107. Method according to claim 106, CHARACTERIZED by the fact that the first purified cannabinoid chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBGV or CBGVA.
[108]
108. The method of claim 107, characterized in that it comprises administering a first purified terpene.
[109]
109. Method according to claim 108, CHARACTERIZED by the fact that the first purified terpene is chosen from bornyl acetate, alpha
Petition 870190082150, of 22/08/2019, p. 115/121
15/17 bisabolol, borneol, camphor, camphor, carene, beta-karyophylene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalol, menthol, beta-mircene, nerolid , ocimene, felandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene or valencene.
[110]
110. The method of claim 102, characterized in that it comprises administering an excipient.
[111]
111. The method of claim 102, characterized in that it comprises administering a second dosage formulation comprising a first purified psilocybin derivative.
[112]
112. Method according to claim 111, CHARACTERIZED by the fact that the first dosage formulation and the second dosage formulation are homogeneous mixtures.
[113]
113. Method according to claim 112, CHARACTERIZED by the fact that homogeneous mixtures have little or no deviation of about 10%.
[114]
114. Method, according to claim 113, CHARACTERIZED by the fact that homogeneous mixtures have little or no deviation of about 5%.
[115]
115. Method according to claim 102, CHARACTERIZED by the fact that the first dosage formulation comprises a first purified psilocybin derivative, a second purified psilocybin derivative and a first purified cannabinoid in a single composition.
[116]
116. Method according to claim 103, CHARACTERIZED in that the first dosage formulation comprises a first purified psilocybin derivative, a second purified psilocybin derivative and a first purified cannabinoid in two or more compositions.
[117]
117. Method according to claim 102, CHARACTERIZED by the fact that the psychological disorder is an anxiety disorder.
Petition 870190082150, of 22/08/2019, p. 116/121
16/17
[118]
118. Method according to claim 117, CHARACTERIZED by the fact that anxiety disorder is chosen from acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, phobia , post-traumatic stress disorder, separation anxiety disorder, social anxiety disorder, substance-induced anxiety disorder or selective mutism.
[119]
119. The method of claim 117, characterized in that it comprises administering an anxiolytic drug.
[120]
120. Method according to claim 119, CHARACTERIZED by the fact that the anxiolytic drug is chosen from alprazolam, an alpha-blocker, an antihistamine, a barbiturate, a beta-blocker, bromazepam, a carbamate, chlordiazepox, clonazepam , chlorazepate, diazepam, flurazepam, lorazepam, an opioid, oxazepam, temazepam or triazolam.
[121]
121. Method according to claim 102, CHARACTERIZED by the fact that the psychological disorder is a depressive disorder.
[122]
122. Method according to claim 121, CHARACTERIZED by the fact that depressive disorder is selected from atypical depression, bipolar disorder, catatonic depression, depressive disorder due to a medical condition, major depressive disorder, postpartum depression, dysphoric disorder premenstrual or seasonal affective disorder.
[123]
123. The method of claim 121, characterized in that it comprises administering an antidepressant.
[124]
124. Method according to claim 123, CHARACTERIZED by the fact that the antidepressant is chosen from buproprion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline and venlafaxine.
Petition 870190082150, of 22/08/2019, p. 117/121
17/17
[125]
125. Method according to claim 102, CHARACTERIZED by the fact that the psychological disorder is a compulsive disorder.
[126]
126. Method, according to claim 125, CHARACTERIZED by the fact that compulsive disorder is chosen from dependence, body dysmorphic disorder, excoriation disorder, accumulation disorder, obsessive compulsive disorder and trichotillomania.
[127]
127. Method according to claim 125, characterized in that it comprises administering a modulator of neurotransmitter activity.
[128]
128. Method according to claim 127, CHARACTERIZED by the fact that the neurotransmitter activity modulator is chosen from aripiprazole, bupropion, citalopram, clomipramine, dextroamphetamine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnaciprine, miretzapine, partazapine, partaxapine, partaxapine, reboxetine, risperidone, sertraline and venlafaxine.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019016489A2|2020-04-07|compositions and methods comprising a psilocybin derivative

---

Boggs et al.2018|Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol

---

WO2019099745A1|2019-05-23|Compositions comprising a psilocybin derivative and a cannabinoid

---

Zawilska2011|Legal highs–new players in the old drama

---

Karila et al.2016|The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences

---

US20200253921A1|2020-08-13|Cannabinoid Formulations

---

Monteiro et al.2013|Update on 1-benzylpiperazine | party pills

---

CA2676139C|2016-04-26|Composition comprising terpene compounds and methods for inhibiting nerve transmission

---

Waters2008|Diagnosis and management of Parkinson's disease

---

Pieprzyca et al.2020|Synthetic cathinones–from natural plant stimulant to new drug of abuse

---

US20210353615A1|2021-11-18|Compositions and methods comprising a combination of serotonergic drugs

---

Varì et al.2019|New psychoactive substances—Synthetic stimulants

---

Sutter et al.2014|Alternative drugs of abuse

---

WO2010017626A1|2010-02-18|Compositions comprising terpene compounds for treating negative sensory phenomena

---

BR112020027080A2|2021-03-30|COMPOSITION AND METHOD FOR TREATING PAIN

---

Freezer et al.2005|Effects of 3, 4-methylenedioxymethamphetamine | and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide

---

BR112020027070A2|2021-03-30|COMPOSITION AND METHOD FOR SAVING OPIOIDS

---

Wood et al.2013|Mephedrone

---

Schep et al.2020|The clinical toxicology of cannabis

---

US20210361679A1|2021-11-25|Compositions comprising a serotonergic tryptamine compound

---

Raw2014|I. IDENTIFICATION

---

Wright et al.2018|Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy

---

Arbo et al.2016|Drugs of Abuse and the Internet

---

Valente2017|Uncovering the hepatotoxic and neurotoxic potential of ß-keto amphetamine | derivates: in vitro mechanistic studies.

---

Petersen et al.2020|Hallucinogens—psychedelics and dissociative drugs

同族专利:

---

公开号 | 公开日

---

EP3579832A1|2019-12-18|

---

CA3052974A1|2018-08-16|

---

EP3579832A4|2020-12-30|

---

US20180221396A1|2018-08-09|

---

JP2020506246A|2020-02-27|

---

CN110740728A|2020-01-31|

---

WO2018148605A1|2018-08-16|

---

US10933073B2|2021-03-02|

---

AU2018217829A1|2019-09-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3192111A|1959-02-16|1965-06-29|Sandoz Ltd|Method of inducing therapeutic tranquilization with psilocybin and psilocin|

---

US6303181B1|1993-05-17|2001-10-16|Electrochemicals Inc.|Direct metallization process employing a cationic conditioner and a binder|

---

FR2783520B1|1998-09-21|2000-11-10|Oreal|NEW CATIONIC 4-HYDROXYINDOLES, THEIR USE FOR THE OXIDIZING DYE OF KERATINIC FIBERS, TINCTORIAL COMPOSITIONS AND DYING PROCESS|

---

US20040034106A1|2001-11-06|2004-02-19|Read Holly Ann|Treatment of anxiety disorders|

---

GB2456183A|2008-01-04|2009-07-08|Gw Pharma Ltd|Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament|

---

GB2514054A|2011-09-29|2014-11-12|Gw Pharma Ltd|A pharmaceutical composition comprising the phytocannabinoids cannabidivarin and cannabidiol |

---

US20160279073A1|2013-10-31|2016-09-29|Full Spectrum Laboratories, Ltd.|Terpene and cannabinoid formulations|

---

NL2018190B1|2017-01-18|2018-07-26|Procare Beheer B V|Psilocybin or psilocin in combination with cannabinoid|GB2571696B|2017-10-09|2020-05-27|Compass Pathways Ltd|Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced|

---

WO2020154811A1|2019-01-31|2020-08-06|Cava Healthcare Inc.|Compounds for increasing mhc-i expression and modulating histone deacetylase activity|

---

EP3920904A1|2019-02-08|2021-12-15|Schedule 1 Therapeutics, Inc.|Compositions comprising cannabinoids and methods of use thereof|

---

EP3955919A1|2019-04-17|2022-02-23|COMPASS Pathfinder Limited|Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin|

---

US10993928B2|2019-04-26|2021-05-04|Natural Extraction Systems, LLC|Compositions comprising non-crystalline forms of cannabidiol|

---

DE102019117739A1|2019-07-01|2021-01-07|Felix Blei|Arylalkylamine, pyrrole, indole, and opiate derivative concentration methods and test kits using this method|

---

WO2021016710A1|2019-07-30|2021-02-04|Tassili Life Sciences, Corp.|Controlled release formulations of multiple active pharmaceutical agents, and psilocybe-derived agents in combination with cannabis-derived agents and methods for their use|

---

WO2021041407A1|2019-08-25|2021-03-04|Caamtech Llc|Alkyl quarternary ammonium tryptamines and their therapeutic uses|

---

WO2021072530A1|2019-10-15|2021-04-22|Tassili Life Sciences, Corp.|Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.|

---

WO2021168082A1|2020-02-18|2021-08-26|Gilgamesh Pharmaceuticals, Inc.|Specific tryptamines for use in the treatment of mood disorders|

---

WO2021188812A1|2020-03-19|2021-09-23|Caamtech, Inc.|Crystalline norpsilocin compounds|

---

US11242318B2|2020-05-19|2022-02-08|Cybin Irl Limited|Deuterated tryptamine derivatives and methods of use|

---

WO2021234608A1|2020-05-19|2021-11-25|Cybin Irl Limited|Deuterated tryptamine derivatives and methods of use|

---

CN111812222A|2020-06-01|2020-10-23|南京品生医学检验实验室有限公司|Method for detecting concentration of antidepressant drug in serum by ultra-high performance liquid chromatography tandem mass spectrometry technology|

---

WO2021243460A1|2020-06-03|2021-12-09|Neonmind Biosciences Inc.|Method for weight loss with therapy|

---

US20220062237A1|2020-08-28|2022-03-03|Small Pharma Ltd|Injectable formulation|

法律状态:
2021-10-19| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201762457123P| true| 2017-02-09|2017-02-09|

---

US201762587395P| true| 2017-11-16|2017-11-16|

---

US201762587431P| true| 2017-11-16|2017-11-16|

---

US201762587410P| true| 2017-11-16|2017-11-16|

---

US201762587419P| true| 2017-11-16|2017-11-16|

---

US201762592320P| true| 2017-11-29|2017-11-29|

---

US201762592307P| true| 2017-11-29|2017-11-29|

---

US201762593021P| true| 2017-11-30|2017-11-30|

---

US201762595336P| true| 2017-12-06|2017-12-06|

---

US201762595321P| true| 2017-12-06|2017-12-06|

---

US201762598767P| true| 2017-12-14|2017-12-14|

---

US201762609115P| true| 2017-12-21|2017-12-21|

---

US201862613360P| true| 2018-01-03|2018-01-03|

---

PCT/US2018/017710|WO2018148605A1|2017-02-09|2018-02-09|Compositions and methods comprising a psilocybin derivative|

---